A rational approach to the design of a leukotriene antagonist. by Tudhope, Stephen Richard.
A RATIONAL APPROACH TO THE DESIGN OF
A LEUKOTRIENE ANTAGONIST
A thesis presented by
Stephen Richard Tudhope, B.Sc
for the degree of
DOCTOR OF PHILOSOPHY
December 1987
Department of Chemistry Research Department
University of Surrey Miles Laboratories Ltd
GUILDFORD Stoke Court
Surrey Stoke Poges
GU2 5XH SLOUGH
Bucks SL2 4LY
ProQuest Number: 10804614
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10804614
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
ABSTRACT
Leukotrienes are newly discovered metabolites of arachidonic acid 
believed to play a mediatory role in the pathogenesis of asthma. 
It was the intention, therefore to develop a leukotriene 
antagonist which may be clinically beneficial in this disease 
state.
The known leukotrienes LTC^, LTD^, and LTE^ were synthesised and 
studied in vitro on a range of animal tissues, which indicated 
the existence of three discrete leukotriene receptors. Synthesis 
of leukotriene analogues aimed at simplifying the agonist 
pharmacophore, resulted in the identification of a highly potent 
agonist of greater structural simplicity than the natural 
leukotrienes. From this starting point, using concepts of 
molecular rigidity and pharmacophoric group displacement, a 
compound was developed which antagonised the effects of the 
leukotrienes on the three receptor systems.
This antagonist, bearing such a broad profile of activity, 
constitutes a major breakthrough in the field of leukotriene 
research.
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Abbreviations used in this text
A Analogue
Ac Acetyl
AMP Adenosine monophosphate
ANT Antagonist
br Broad
c Concentrated
d Doublet
ether Diethyl ether
EtOAc Ethyl acetate
FA Full agonist
FAB Fast atom bombardment
h Hours(s)
Hist. Histamine
HMPA Hexamethylphosphoramide
HPETE Hydroperoxyeicosatetraenoic acid
HPLC High pressure liquid chromatography
I Inactive
LT Leukotriene
LTA,
4
5 (S),6(S)-oxido-7(E),9(E),11(Z),14(Z)-eicosatetraenoic 
acid
LTA,-Me 
4
Methyl 5(S),6(S)-oxido-7(E),9(E),11(Z),14(Z)- 
eicosatetraenoate
LTB,
4
5(S),12(R)-Dihydroxy-6(Z),8(E),10(E),14(Z)- 
eicosatetraenoic acid
LTC^ 6 (R)-S-(Glutathione)- 5 (S)-hydroxy-7(E),9(E),11(Z),14(Z)
-eicosatetraenoic acid 
LTD^ 6 (R)-S-(Cysteinylglycine)-5(S)-hydroxy-7(E),9(E),11(Z),
14(Z)-eicosatetraenoic acid 
LTE4 6 (R)-S-(Cysteine)-5 (S)-hydroxy-7 (E) , 9 (E) , 11 (Z) , 14 (Z) -
eicosatetraenoic acid 
m Multiplet
M  Molar concentration
Me Methyl
min Minute(s)
mp Melting point
MS Mass spectrum
n Normal
NA Noradrenaline
nmr Nuclear magnetic resonance
p Preparative
PA Partial agonist
PBS Phosphate buffered saline
q Quartet
RP Reverse phase
s Singlet
t Triplet
TEA Triethylamine
THF Tetrahydrofuran
tic Thin layer chromatography
UV Ultra-violet
WA Weak agonist
INTRODUCTION
DISCOVERY OF LEUKOTRIENES
In 1938 Feldberg and Kellaway* demonstrated the release of a
substance from dog and monkey lung, in response to stimulation by
cobra venom, which caused a delayed and slow contraction of the
2
guinea-pig jejunum. Two years later Kellaway and Trethewie
described the release of a similar substance upon specific
antigen challenge by guinea-pig heart-lung preparations and
3 4
termed this SRS (slow-reacting substance). Brocklehurst * 
subsequently showed that a slow-reacting substance released 
during anaphylaxis of guinea-pig, rabbit, monkey and human lung, 
termed SRS-A (slow-reacting substance of anaphylaxis) was 
unaffected by the histamine antagonist mepyramine and so began 
the speculation of an involvement of SRS-A in human asthma.
SRS-A could only be produced in very small quantities from 
biological systems which for many years precluded detailed 
structural analysis. Furthermore the biologically derived 
material was crude and it wasnft until improved chromatographic 
techniques became available that purified SRS-A could at last be 
studied. Bach and Brashler"* demonstrated that increased SRS 
production was obtained from peritoneal cells challenged in vitro 
and in vivo with the calcium ionophore A23187 which was further 
enhanced by the presence of certain mercaptans, especially 
c y s t e i n e ^ * W i t h  the improved purification techniques described
g
by Morris, Taylor et al in 1978, utilising recently invented
-1-
high pressure liquid chromatographic (HPLC) systems, the door was 
finally open to discovering the identity of the elusive SRS.
Early studies on crude SRS had suggested that it was an
9 10
unsaturated acidic lipid containing sulphur possibly as a
11 12
sulphate ester. In 1977 Bach and Jakschik independently
reported evidence that SRS was a metabolite of arachidonic acid,
although they disagreed as to whether it was a product of the
lipoxygenase or cyclooxygenase pathway. Although the addition of
mercaptans to peritoneal cell incubations had been shown to
markedly improve the yield of SRS it was uncertain whether the
mercaptans merely stimulated SRS release or were actually
6 13
incorporated into the molecule. Radiolabelling studies * were
inconclusive, probably due to the minute quantity of material
14
being studied. Bach and Brashler , however, studying the 
stimulation of SRS release by a wide range of mercaptans found 
that only mercapto carboxylic acids were effective. Furthermore 
the SRS-type products appeared to be non-identical and they thus 
proposed the incorporation of mercaptans into SRS by the trapping 
of a labile intermediate.
In 1979 Borgeat and Samuelsson^ detected an unstable 
intermediate in the transformation of arachidonic acid into 
dihydroxy acids in leukocytes. The dihydroxy acids were 
characterised by HPLC and Mass spectrometry as
5,6-dihydroxyeicosatetraenoic acid and
-2-
5,12-dihydroxyeicosatetraenoic acid and they thus proposed that 
the unstable intermediate was the epoxide
5.6-oxido-7,9,11,14-eicosatetraenoic acid. In the same year 
Samuelsson et a l ^  characterised a cysteinyl derivative of
5.6-oxido-7,9,11,14-eicosatetraenoic acid as the SRS produced by 
murine mastocytoma cells stimulated with A23187 in the presence 
of cysteine.
Samuelsson et a l ^  introduced the term leukotriene to describe
the newly discovered family of arachidonic acid metabolites
containing the unstable epoxide intermediate (Leukotriene A ) , its
enzymatic hydrolysis product 5,12-dihydroxyeicosatetraenoic acid
(Leukotriene B) and the thiopeptidyl derivative (Leukotriene C ) .
It soon became apparent, however, that SRS’s from different
sources were slightly different from one another, varying in the
18 19 20 21
peptide substituent attached to C-6 * * * . An elegant
22 23
synthesis by Corey ejt al * confirmed the structures of the
natural products as those resulting from addition of either
glutathione, cysteinylglycine or cysteine to C-6 of leukotriene
A. These are now known as leukotrienes C., D, and E.
4 4 4
24 25
respectively (Fig. 1). Thus SRS, and indeed SRS-A , are
mixtures of the potent spasmogens leukotriene C^ (LTC^),
leukotriene (LTD^) and leukotriene E^ (LTE^); the relative
proportions of each varying from one source to another, depending
on the local enzyme population.
-3-
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It is now known that glutathione S-transferase converts
leukotriene (LTA^) into LTC^ which is metabolised to LTD^ by a
18 26
Y-glutamyltranspeptidase * . LTD^ is further metabolised by
24 27
an aminopeptidase to LTE^ which was shown in the rat to be
28
further metabolised to N-acetyl LTE^,. A recent study in man , 
however, has shown that LTE^ is the end metabolite of LTC^, being 
predominantly excreted in the urine.
The term leukotriene was derived from leukocytes, the cells in 
which the family was first identified and a common structural 
feature, the conjugated triene; the subscript denoting the total 
number of double bonds in the molecule^.
Leukotrienes are produced from a number of inflammatory cells
including leukocytes, eosinophils, macrophages and mast cells 
29
(see review ) by a variety of stimuli including immunological 
challenge and calcium ionophore stimulation. However, as the 
majority of cell types contain the precursor to leukotriene 
formation, arachidonic acid, as a component of their cell 
membranes, it is tempting to speculate that most mammalian cells 
have the capacity to produce leukotrienes.
BIOLOGICAL ACTIVITY OF LEUKOTRIENES
The sulphidopeptidyl leukotrienes (LTC^, LTD^ and LTE^) are
potent contractile agents on many smooth muscle tissues in a
. _ . . 30,31,32
variety of species
-5-
In general they have 100-1000 times the potency of histamine on a
33
molar basis, are vasoconstricting and, furthermore, increase
34
vascular permeability giving rise to oedema.
35
Leukotriene is a potent chemotactant , attracting neutrophils 
which can subsequently cause major tissue damage. Thus the 
family of leukotrienes could play important mediatory roles in 
the clinical diseases associated with asthma, allergy and 
inflammation^.
The association of leukotrienes with the human asthmatic state
began with the discovery of SRS-A in specifically challenged
4
human asthmatic lung effluents . Subsequent studies with
synthetic peptido leukotrienes have shown that they
37
preferentially constrict the peripheral airways unlike the 
prostaglandins which selectively act on the larger passages.
This may explain the inability of prostaglandin synthesis 
inhibitors such as indomethacin to be effective in asthma therapy 
(where peripheral airways constriction is a major problem) and 
enhances the belief that leukotriene antagonists or synthesis 
inhibitors may be clinically beneficial.
The leukotrienes have been shown to contract smooth muscle tissue 
via a direct and an indirect mechanism. In guinea-pig lung 
parenchyma leukotrienes cause the release of thromboxane A^ which
enhances the direct effect of leukotriene-induced
„ 38,39,40
contraction
-6-
Leukotriene B^, a non-peptido leukotriene, contracts guinea-pig
lung parenchyma solely via thromboxane release, having no
41
direct action itself . For this reason the general use of the 
word ’leukotriene1 in this report shall henceforth be limited to 
the sulphidopeptidyl leukotrienes LTC^, LTD^ and LTE^, as it is 
their direct mode of action on smooth muscle tissue that is of 
major interest herein.
The reported biological profiles of the leukotrienes on various
tissues have been somewhat conflicting over the years. This is
probably due to a combination of four factors: The chemical
42
instability of leukotrienes giving purity and quantitation
problems; metabolic instability; indirect effects caused by
LT-induced mediator release and last but not least, 'biological
variability1. The first problem may be overcome by using freshly
synthesised material temporarily stored under an inert atmosphere
at very low temperature, thawing immediately prior to use as
19
repeated thawing and freezing has been shown to be detremental
43
to activity. Secondly, enzyme inhibitors added to the tissue
baths remove the possibility of leukotriene metabolism during the
course of an experiment and thirdly the use of cyclooxygenase
44
inhibitors such as indomethacin or meclofenamic acid inhibit 
prostaglandin and thromboxane production. Although biological 
variability is a persistant problem, generation of high ’n ’ 
values and adoption of the above precautions should minimise many 
errors.
-7-
FPL55712
45
The SRS-A antagonist FPL 55712 (Fig. 2) has been known for many
46
years and reported to be a specific leukotriene antagonist
Its failure to work in vivo though, has been attributed to a very
47
short half-life associated with a rapid uptake mechanism . Many 
structural analogues of FPL 55712, however, have also been 
clinically unsuccessful, suggesting an inherent flaw in its mode 
of action.
FPL 55712 has been reported to be a competitive antagonist of
48 43
LTD^ on both the guinea-pig ileum and trachea . However, FPL
43
55712 fails to antagonise LTC^, on the trachea and 
49 50
parenchyma * suggesting a heterogeneity of leukotriene
receptors in guinea-pig airways. This is not altogether
51 52
surprising in the light of histamine and adrenergic receptor
investigations, especially as the leukotrienes are apparently
equally ubiquitous.
OH
OH
Fig. 2
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CLINICAL STUDIES
Recent clinical studies in man using inhaled leukotrienes have
been somewhat conflicting. It is universally agreed though, that
leukotrienes cause immediate long-lasting bronchoconstriction
(reminiscent of their in vitro activity) with a far greater
37 53 54 55
potency than histamine. Holroyde and others * * * suggested
that the leukotrienes were selective for the small airways, which
agreed with similar animal experiments”*^* although Smith‘d  and 
58
Barnes found that leukotrienes constricted both the upper and 
lower airways, in agreement with human in vitro data’* ^ * ^ * ^ .  
Studies with human asthmatics'*”* indicated a hyperreactivity to
LTD^ although a similar increased sensitivity was also shown for
57 62
methacholine . Griffin £t al showed hyperreactivity to
histamine in human asthmatics but failed to find any such effect
54
with LTD^. Weiss et al showed that the LTD^-induced
bronchoconstriction in man was unaffected by pretreatment with
aspirin, implying that it is a direct leukotriene effect and not
37
mediated by cyclo-oxygenase. In one study FPL 55712 was shown 
to partly inhibit bronchoconstriction in one of two normal 
subjects, although a cough response was obtained to inhaled 
leukotrienes in this subject which has not been substantiated by 
other workers.
Thus the role of leukotrienes in human asthma remains equivocal 
and will probably remain so until specific antagonists are
-9-
developed. Specific leukotriene antagonists may also assist the 
clinical classification of respiratory diseases and in particular 
what today is loosely termed ’asthma’.
STRUCTURE-ACTIVITY RELATIONSHIPS
The structure-activity approach to drug design has been utilised
to improve many existing drugs found in nature and to improve
drug profiles (potency, side-effects etc) of man made therapeutic
63
agents; for example, the development of lidocaine from cocaine,
6 A
with optimal local anesthetic properties and isoproternol from 
adrenaline, with m a x i m a l -adrenergic properties.
The use of structure-activity relationships in the design of 
specific antagonists from agonists, however, is a relatively new 
science and has had limited success to date. Black et: al 
successfully used this approach to design Cimetidine^, a 
specific H^-receptor antagonist. Further structure-activity 
studies in the Glaxo laboratories produced Ranitidine, a highly
potent and specific I^-receptor antagonist currently marketed,
66
like Cimetidine, for the treatment of stomach ulcers
The decision to approach the development of a LT-antagonist from 
a structure activity study of the agonists was based on the 
rationale that the known LT-antagonist FPL 55712, and analogues 
thereof, were ineffective against LTC^ on guinea-pig airway 
smooth muscle, implying a different structural requirement for
-10-
the relevant receptors. Furthermore it was hoped that a 
systematic analogue approach would indicate differences in 
receptor systems assisting pharmacological evaluation of the test 
tissues.
RECEPTOR THEORY
The concept of specific recognition sites for certain molecules
or drugs is very old indeed. Titus Lucretius Carus envisaged
sensations such as taste to be a result of such a specific
interaction in the didactic poem De Rerum Natura circa 50BC.
Somewhat nearer to our own time, Lan g l e y ^  used the term
"receptive substance" to describe the site where nicotine and
68
curari act; but it was Ehrlich who coined the term receptor to 
describe such specific molecular recognition sites.
The early treatment of receptor theory (Clark [1926])^ supposed 
that the magnitude of a pharmacological effect was directly 
proportional to the fractional receptor occupancy and that the 
reaction between drug and receptor obeyed Langmuirs adsorption
isotherm^. Although this crude mathematical treatment of
71 72
receptor theory was later improved by Ariens and Stephenson
to include terms such as efficacy (the capacity of a drug to
initiate a response) and the principle of receptor reserve (the
ability of a drug to elicit maximal tissue response without total
receptor occupancy), it gave little or no insight into the
mechanism of receptor activation.
-11-
The receptor theories of Clark, Ariens and Stephenson were based
on receptor occupancy and were further developed and unified by 
73 74
Furchgott . Paton , however, proposed the rate theory of 
receptor activation which postulated that the biological response 
was proportional to the rate at which the drug associates with 
the receptor and not the number or proportion of receptors 
occupied.
Thus, under the rate theory, a full agonist was a compound that 
combined and dissociated rapidly from the receptor so that many 
Associations' could be made leading to maximal activity. An 
antagonist would theoretically dissociate very slowly thus 
impeding further activation.
Although the rate theory explained why some drugs were agonists 
and other antagonists, it failed to be consistent with many 
observed p h e n o m e n a ^ ' ^  and was generally considered to be of 
little use.
Until this time mathematical principles were being applied to
receptor-ligand interactions without consideration of events at
78
the molecular level. Belleau then proposed the macromolecular
purturbation theory based on the enzyme-substrate induced fit 
79
model of Koshland . The macromolecular purturbation theory 
proposed two types of drug-receptor interactions. The first 
being that induced by agonists, termed a specific conformational 
purturbation (SCP) and the second being a non-specific
-12-
conformational purturbation (NSCP), induced by antagonists. The 
SCP was proposed to lead to a biological response whereas the 
NSCP did not. Partial agonists were explained by being in 
equilibrium between SCP and NSCP. This finally linked the 
occupational theory with events at the molecular level and 
explained in mechanistic terms the previous occupational theory 
enigmas such as affinity and efficacy.
Fig. 3 represents the macromolecular purturbation theory where a 
receptor [R] combines with ligand[L]. This can give rise to the 
antagonistic complex (NSCP) [RL] or the agonistic complex (SCP) 
[RLj*. The affinity of interaction is given by the kinetic rate
[RL]
[R] + [L]
\ j
[RL] *
Fig. 3
constants or and the efficacy of the drug in question by
-13-
A further description of partial agonist effects and tissue 
dependance is given in a review by Kenakin^.
We thus have a working schematic hypothesis explaining previously 
confused terms such as affinity and efficacy. However, the 
medicinal chemist requires an understanding of the molecular 
interactions effecting binding and activation of a receptor.
The binding of ligand to receptor is highly specific; indeed 
chiral specificity is an often used prerequisite for evidence of 
a receptor-mediated effect. Thus on the molecular scale a 
three-dimensional electronic network is 'recognised* by the 
receptor which probably takes the form of bonding between certain 
groups on the receptor and on the ligand. Such important sites 
on the ligand are termed 'pharmacophoric groups' and their active 
spacial arrangement is termed the receptor 'pharmacophore'.
[H] + IL] [RL] *
[RL]
Fig. 4
-14-
A diagramatic representation of receptor activation is shown in 
figure 4. In this picture it can be seen that the efficacy term 
is determined by the energetics of the interaction between ligand 
and receptor. For an agonist of high efficacy the majority of 
ligand-receptor complexes will be found in the activated state. 
This is represented by a conformational change in the active site 
of the receptor which elicits its messenger role by a 
simultaneous conformational change at a distinct site on the 
receptor protein. The receptor may, for example, be coupled to a 
guanidine nucleotide protein so that receptor activation 
decreases the intracellular levels of cyclic-AMP and thus causes 
the cell to contract. An antagonist, by definition, will bind to 
the ground state of the receptor and not elicit a response.
The aim of ’a rational drug design by analogue approach' is to 
firstly identify the pharmacophoric groups (shown in fig. 4 by 
the triangle, square and semicircle) and then to construct a 
ligand which will bind to the receptor in the ground state ([RL]) 
and be incapable of activating the receptor i.e. have zero 
efficacy.
There are three popular approaches to such a design:-
1. Removal of a pharmacophoric group essential to receptor 
activation and replacing the lost affinity by the 
introduction of a new group which binds to a neighbouring 
'accessory' or 'auxiliary' site.
-15-
2. Shortening or lengthening the interatomic distances between 
pharmacophoric groups to favour binding to the ground state 
conformation of the receptor.
3. Introducing molecular rigidity in the ligand to favour 
binding to the ground state receptor and inhibit the 
conformational change.
This thesis will discuss the application of aspects of the above 
principles in the design of leukotriene antagonists.
-16-
The synthesis and biological evaluation of reference compounds
Introduction
To facilitate a detailed study of leukotrienes and leukotriene 
analogues it was necessary, firstly, to obtain sufficient 
quantities of the natural agonists for reference purposes. As 
only minute quantities could be isolated from biological sourses 
and the cost of synthetic material (when available) prohibitive, 
it was apparent that a workable synthetic route had to be found.
The structural complexity of leukotrienes posed many synthetic
problems, notwithstanding two chiral centres and four double
bonds in leukotriene giving a possible sixty four geometrical
and optical isomers. A number of elegant syntheses of
81-88
leukotriene A^ have been reported since Corey first
89
prepared racemic LTC^ . These mostly utilised the chiral 
epoxide intermediate _1 (fig. 5), constructing the remainder of 
the molecule by a variety of Wittig extensions.
C 0 2C H 3
I
Fig. 5
-17-
83
1^ has been prepared from a number of chiral building blocks ,
81 85
but mainly sugars such as D-ribose , L-arabinose and
86—88
2-deoxy-D-ribose . An alternative method of introducing a
90
chiral epoxide is by Sharpless epoxidation of an allylic
alcohol which has also proved effective in the syntheses of 
.91,92
86
Of the synthetic routes reported, that outlined by Rokach to
yield the epoxyaldehyde 1^ appeared the most promising, and with a
few modifications was largely adopted. The remainder of the
molecule was constructed by Wittig extension as described by 
93
Ernest to give enantiomerically pure leukotriene (Fig 6).
FPL 55712 was required as a reference antagonist to characterise
the biological test systems. That is, to discover whether or not
the leukotriene-induced contractions of various tissues were
antagonised by this compound. FPL 55712 was prepared in
94
multigram quantity by the method of Appleton et al (Fig. 8). 
Leukotriene Synthesis
2-Deoxy-D-ribose was extended via Wittig reaction with 
methoxycarbonylmethylenetriphenylphosphorane to give methyl 
5(S),6(R),7-trihydroxyhept-2(E)-enoate (II). The methyl ester 
was preferred as it afforded a crystalline solid compared with a 
gummy oil for the reported ethyl ester prepared via an analogous 
reaction with ethoxycarbonylmethylenetriphenylphosphorane.
-18-
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Triphenylphosphine oxide was removed by aqueous extraction of the 
product, and recrystallisation from dichloromethane/ether removed 
the C-glycoside by-product which is produced by intramolecular 
Michael addition under the reaction conditions.
Catalytic hydrogenation of (II) was effected over 10% palladium 
on carbon in ethyl acetate to afford the crystalline product 
(III), methyl 5(S),6(R),7-trihydroxyheptanoate. Tosylation in 
pyridine at -10°C selectively yielded the primary tosylate (IV) 
which was again purified by recrystallisation. The tosylate was 
prepared in preference to the reported mesitylene sulphonyl 
derivative because it was found to cyclise more readily in the 
following step. Thus treatment of (IV) with potassium carbonate 
in methanol afforded the terminal epoxide (V) which rearranged on 
prolonged base treatment to yield methyl 7-hydroxy-5(S),6(S)- 
oxidoheptanoate (VI) as a colourless oil.
Collins oxidation of (VI) gave the key intermediate methyl
7-oxo-5(S),6(R)-oxidoheptanoate (I), which condensed with
4-oxobut-2(E)-enylidenetriphenylphosphorane (prepared by the
95 96
method of Berenguer et al * ) to give a mixture of the 7-cis
and trans forms of methyl 5 (S),6(S)-oxido-ll-oxo-7,9(E)- 
undecadienoate. Iodine-induced isomerisation afforded the 
’all-trans1 configuration, (VII), as a crystalline solid.
3(Z)-Nonenyltriphenylphosphonium tosylate was prepared by the 
93
method of Ernest and the resulting ylide reacted with (VII) in
-20-
the presence of HMPA to yield exclusively the desired cis- 
configuration of methyl 5 (S),6(S)-oxido-7(E),9(E),11(Z),14(Z)- 
eicosatetraenoate, LTA^-Me (VIII).
LTC^, LTD^ and LTE^ were prepared by addition of protected
glutathione, cysteinylglycine and cysteine respectively to
LTA^-Me in basic methanol followed by deprotection (Fig. 7). The
reaction selectively takes place at the activated C-6 position to
afford the desired 5(S),6(R) stereochemistry of the product.
A novel UV method of following the reaction between LTA^-Me and
thiol was developed. LTA^-Me exhibits a A max at 280nm as do the
6-thioether derivatives (LTC., LTD., LTE.); treatment of LTA.-Me
4 4 4 4
with dilute mineral acid, however, instantaneously produces a
mixture of methyl dihydroxyeicosatetraenoates which have a A max
at 270nm. Thus the reaction of LTA.-Me with thiol is deemed to
4
be complete when acidification of a UV sample does not affect the 
recorded spectrum maxima.
Hydrolysis of the ester functions plus removal of the 
trifluoroacetyl group was conducted in a saturated solution of 
lithium hydroxide in 50% aqueous tetrahydrofuran following the 
reaction progress by RP HPLC. When complete saponification had 
been achieved the product was de-salted on a Reverse Phase (RP) 
plug and stored in 20% ethanol-phosphate buffered saline (PBS) 
pH7.2 under argon at -70°C.
-21-
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Synthesis of FPL 55712
Resacetophenone (XV) was converted into 4-0-allylresacetophenone
(XVI) by the action of allyl bromide in acetone in the presence
97
of potassium carbonate . The regiospecificity of this 
O-alkylation, shown by the absence of 2-0-allylresacetophenone in 
the product, indicates substantial intramolecular chelation • 
between the acetyl and ortho-hydroxyl groups (fig 9); thus 
reducing the acidity of the ortho-hydroxyl group.
4-0-Allylresacetophenone (XVI) underwent Claisen rearrangement at 
elevated temperature to give 3-allylresacetophenone (XVII) with 
some decomposition. The product was purified by sublimation in 
high yield, a technique whichgave excellent results on large 
scale preparations and a product of high purity.
The Claisen rearrangement appeared to occur regiospecifically as
no 5-allylresacetophenone was observed in the product. The 
97
proposed mechanism requires the presence of a formal double 
bond between the sites of migration, which favours the observed
OH Fig. 9
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product due-to the chelation vide supra between neighbouring 
acetyl and hydroxyl groups (Fig. 10).
Fig. 10
Catalytic hydrogenation of 3-allylresacetophenone (XVII) was 
effected in ethanol under a slight pressure of hydrogen with 10% 
palladium on carbon catalyst. Stopping the reaction after the 
absorption of one equivalent of molecular hydrogen gave
3-propylresacetophenone (XVIII) in good yield. It was noticed, 
however, that if the reaction was allowed to continue after the 
theoretical uptake of hydrogen, absorption continued at a 
slightly slower rate. Complete hydrogenation of a sample of
(XVII) resulted in reduction of the aromatic nucleus and the 
carbonyl group. The unexpected ease of this reduction clearly 
illustrated the reduced aromaticity of ortho- 
hydroxyacetophenones.
Condensation of the phenol (XVIII) with epichlorohydrin in basic 
ethanol afforded the epoxide (XIX) in good yield. Claisen 
condensation of (XVIII) with diethyl oxalate under the action of 
a strong base gave the intermediate cf,y-diketo ester ('XXIII) 
(Fig. 11), which cyclised smoothly in acidic ethanol to give the 
chromone (XX).
-25-
Nucleophilic addition of the chromone (XX) to the epoxide (XIX), 
promoted by N-benzyltrimethylammonium hydroxide in refluxing 
dimethylformamide gave the ethyl ester of FPL 55712 (XXI) which 
was saponified by the action of sodium hydrogencarbonate in 
refluxing ethanol to give the sodium salt FPL 55712 (XXII).
0
HO
XXIII
Fig. 11
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Pharmacological evaluation of reference compounds
Introduction
The isolated guinea-pig ileum has been the tissue of choice for
the detection of leukotrienes since the discovery of SRS. This
tissue is highly sensitive to leukotrienes, the effects of which
are reportedly antagonised by the leukotriene antagonist FPL 
98
55712 . The guinea-pig lung parenchymal preparation has also
been shown to be leukotriene sensitive but FPL 55712 fails to 
antagonise the LTC^-induced responses in this tissue"^. The 
differential effects of FPL 55712 in these two systems suggested 
a heterogeneity of leukotriene receptors and for this reason they 
were adopted as contrasting tissue preparations for the 
evaluation of leukotriene and leukotriene-analogue activities.
99
Following the disclosure by Krell of a homogeneous FPL 55712- 
insensitive receptor population on ferret trachea, a study by
Cuthbert*^ resulted in the inclusion of the ferret spleen
preparation in the bank of test systems for leukotriene analogue 
evaluation. The ferret spleen was adopted in preference to the 
reported tracheal preparation as it exhibited an identical 
biological profile but with greater consistency.
Reported herein are the studies of Gardiner et a l ^ ^  using the
reference leukotrienes C . , D, and E. and FPL 55712 to give
4 4 4
preliminary receptor classification which is later enhanced
by the leukotriene analogue studies described in Chapters 2 and 3 
of this thesis.
Materials
The following drugs were used:- histamine acid phosphate, 
noradrenaline and indomethacin (Sigma), L-cysteine and L-serine 
(SAS Pharmaceuticals), boric acid and sagatal (BDH Chemicals 
Ltd), LTC^, LTD^, LTE^ and FPL 55712 (synthesised as described 
earlier).
_2
Indomethacin (3 x 10 M) was dissolved in absolute ethanol and 
further dilutions prepared using phosphate buffered saline pH 
7.2. All other test drugs were dissolved in phosphate buffered 
saline pH 7.2 and added to the tissue bath in a volume not 
exceeding 100 pi. The concentration of each drug refers to the 
final bath concentration.
Tyrodes solution consisted of the following ANALAR grade
substances: NaCl, 137 mM; KC1, 2.7 mM; CaCl, 2.4 mM; MgCl,
2.1 mM; NaH2P04> 0.5 mM; NaHC03 11.9 mM; D-glucose, 9.2 mM. This
“6
Tyrodes solution routinely contained 3 x 10 M  indomethacin.
Experiments in which enzyme inhibition was studied involved the
inclusion to Tyrodes solution of L-cysteine (10 m M ) , L-serine
43
(45 mM) and boric acid (45 m M ) .
-28-
Methods
Guinea-Pig Ileum
Male Dunkin Hartley guinea-pigs (400-450 g) were sacrificed by 
cervical dislocation and the abdomen opened. The ileum was 
removed and 3 cm segments cut and suspended in 10 ml tissue bath 
containing Tyrodes solution and indomethacin (3 x 10 ^ M) at 37°C 
aerated with carbogen (95 % 5 % CO^). The tissues were
attached to Harvard isotonic transducers with a load of 1 g and
washed at 10 min intervals until equilibrium was attained.
—4 —4
Histamine (10 M  and 3 x 10 M) was added cumulatively to
achieve maximal tissue contraction. The leukotrienes were then 
separately evaluated using a cumulative dosing procedure and 
expressed as a percentage of the maximal histamine response.
Guinea-pig Lung
Male Dunkin Hartley guinea-pigs (400-450 g) were sacrificed by
cervical dislocation and the thorax opened. The lungs were
removed and after discarding the peripheral layer, 3 cm
longitudinal sections were cut and suspended in 10 ml tissue
—6
baths containing Tyrodes solution and indomethacin (3 x 10 M) 
at 37°C aerated with carbogen. L-Cysteine and serine-borate 
complex were routinely added to Tyrodes solution for this test 
system. The tissues were attached to Hugo Sachs isotonic 
transducers with a load of 0.5 g and washed at 30 min intervals
-29-
-4 -4
until equilibrium was attained. Histamine (10 M  and 3 x 10
M) was added cumulatively to achieve maximal tissue contraction.
The leukotrienes were then separately evaluated using a
cumulative dosing procedure and expressed as a percentage of the
maximal histamine response.
Ferret Spleen
Adult male ferrets (Froxfield Animal Supplies) weighing 1090 ± 65 
g were sacrificed by an intraperitoneal injection of Sagatal (10 
mg.kg *). The spleen (10.4 ± 1.5 g) was removed, placed in 
Tyrodes solution and cut into longitudinal strips 
(30 mm x 5 mm; 212 ± 15 m g ) .
The strips were mounted in 10 ml tissue baths containing Tyrodes
solution at 37°C aerated with carbogen. Indomethacin 
—6
(3 x 10 M) was routinely added to the Tyrodes solution. The 
tissues were attached to isometric (Statham UC2) transducers 
under an initial tension of lg and allowed to equilibrate over 
1 h whereupon a maximal contraction (5.1 ± 0.25 mg tension per mg 
wet tissue weight) was induced by noradrenaline (10 M) . Upon 
returning to their original baseline tone a single cumulative 
dose-response curve for the test compound was constructed per 
tissue and the results normalised as a percentage of the maximal 
contraction induced by noradrenaline.
-30-
Statistical Analysis
EC^-q (concentration of an agonist producing 50% of its maximal
response) were calculated using a least squares regression
analysis using data from the ’straight line’ portion of the
dose-response curves. Antagonism was quantified using Schild 
102
analysis and expressed as a pA^ value. When the slope of the 
Schild plot was significantly different from unity or for single 
dose antagonism studies, the antagonism was express as pK 
determined using the formula:
K_ = (Antagonist concentration) x (dose ratio-1) *
B
-31-
RESULTS
i) Guinea-pig ileum
In contrast to histamine-induced contractions of the guinea-pig
ileum, leukotriene C.-, D.-, E.-induced contractions were slower
4 4 4
in onset and took longer to reach their maximal effect (Fig. 12).
This is consistent with the results described for crude SRS which
was discovered on this tissue and hence the acquired terminology.
It is also apparent from Fig. 12. however, that the LTC^-induced
contractions are even slower to reach their maximum than LTD. or
4
LTE^ which had similar profiles. Furthermore, the contraction 
induced by LTC^ was maintained until the bath fluid was changed 
whereas LTD^ and LTE^ induced responses were transient, returning 
to baseline after the maximal response had been achieved.
The dose-response curves of LTC^, and E^ are shown in Fig. 13.
The results are expressed as a percentage of the maximal response
attained by LTD^. It can be seen that LTC^ achieved a greater
maximal contraction than LTD^ although the E C ^ s  are similar
[LTC4 EC50 = (4.6 ± 0.8) x 10"9 M; LTD^ EC5Q = (3.2 + 1.2) x 
-9
10 M] hTE^, however, is less effective and less potent 
[LTE^ EC^q = (1.0 ± 2.2) x  10 ^ M] than LTC^ or LTD^ in this 
tissue.
-32-
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The presence of the enzyme inhibitors L-cysteine and serine 
borate did not significantly affect the contractions induced by 
LTC^ on this tissue (Fig. 14) indicating that there is little or 
no metabolism occurring under the experimental conditions. LTD^ 
was evaluated in a similar manner and again no significant 
difference in its maximal activity occurred (data not shown).
In the light of these results and the problem of spontaneous 
activity induced by the enzyme inhibitors in this tissue, the 
following experiments were performed in the absence of enzyme 
inhibitors.
FPL 55712 was found to be a competitive antagonist of LTD^, 
giving a Schild plot with slope of unity and a pA^ value of 6.9 
(Fig. 15). Although FPL 55712 antagonised the effects of LTC^ on 
this tissue, it was of a non-competitive nature making 
calculation of a pA^ value invalid (Fig. 16). FPL 55712 was also 
shown to be a good antagonist of LTE^ (Fig. 17) although a pA^ 
value could not be calculated from this experiment. The dose 
response curves of LTE^ were shifted to a similar degree by a 
given concentration of FPL 55712 as those of LTD^; LTC^ is 
apparently less effected by the same concentration.
As LTE^ had a significantly lower maximal efficacy than either 
LTC^ or LTD^, it was possible to test for partial agonist activity 
of LTE^ against LTC^ and LTD^. The results shown in Figs. 18 and 
19 clearly indicate that LTE^ was a partial agonist of LTD^ and
-38-
LTC^ although the antagonism of LTD^ appears greater than thafe of
LTC. for the lower concentration of LTE.. LTE. had no effect on 4 4 4
the histamine dose-response curve at the same concentration (data 
not shown).
ii) Guinea-pig Lung
Leukotriene C^- and D^-induced contraction of guinea-pig lung
parenchymal strip preparations were much slower than that induced
by histamine, taking approximately 20-25 minutes to reach maximal
effect (Fig. 20). The contractions were long-lasting and
difficult to wash out. Although the E C - ' s  of LTC., LTD. and
50 4 4
LTE. were similar [LTC. EC_n = (4.2 ± 1.5)x 10 8 M; LTD. ECcn =
4 4 50 4 50
(4.6 ± 2.4)x 10“8 M; LTE^ EC5Q = (2.7 ± 2.7)x 10~8 M ] , the
maximal attainable contractions differed. LTC. was more
4
efficacious than LTD^ which, in turn, was more efficacious than 
LTE4 (Fig. 21).
The lower efficacy of LTD^ and LTE^ made it possible to test for
partial agonism at the LTC^ receptor. Fig. 22 and Fig. 23 show
the effect of a 10 ^ M  dose of LTD^ and LTE^ respectively on the
LTC^ dose-response curve. The higher doses of LTC^ are
apparently antagonised by both LTD^ and LTE^, indicative of 
partial agonist activity.
-39-
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FPL 55712 failed to antagonise either the LTC^- or the 
LTD^-induced contractions in this tissue (Fig. 24,25) but 
potentiated the higher doses of LTD^-induced contraction.
iii) Ferret Spleen
LTC^, and LTD^ are potent contractants of this tissue, capable of 
achieving >80% of the maximal noradrenaline response (Fig. 26). 
The leukotriene-induced contractions, however, were slower in 
onset than those induced by noradrenaline, taking approximately 4 
minutes to reach a maximum compared with 30 seconds - 1 minute 
for the adrenergic receptor agonist. LTC^ and LTD^ have similar 
maximal efficacies on this tissue with E C ^ ’s of (2.8 ± 0.7) x 
10 ^ M  and (3.7 ± 0.7) x 10  ^ M  respectively compared with 
noradrenalines EC,.q of (5.3 ± 0.5) x 10 ^ M. LTE^, however, was 
a poor agonist achieving only 20% of the maximal contraction of 
LTD4 at 10“5 M  (Fig. 27).
The presence of enzyme inhibitors did not significantly affect
the dose-response curves of either LTC^ or LTD^, implying a lack
of metabolism in this system (Fig. 28). Furthermore, FPL 55712
was without effect on either the LTC. or LTD.-induced
4 4
contractions of this tissue (Fig. 29,30).
LTE^, however, was found to be a partial agonist in this tissue, 
antagonising the effects of both LTC^ and LTD^ in the presence or 
absence of enzyme inhibitors (Figs 31,32). It did not affect the
-44-
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responses induced by noradrenaline. The dissociation constant
(kp) for LTE^ at 10 was determined using the Schild regression
technique for partial agonists and was found to be 2.5 x 10 ^ for
LTD, and 1.03 x 1C)”6 for LTC,.
4 4
DISCUSSION
The rank order of potency on guinea-pig ileum was found to be 
LTC^ > LTD^ > LTE^. The lower efficacy of LTE^ enabled it to be 
tested as a partial agonist against LTC^ and LTD^ and indeed it 
was found to antagonise the responses to both full agonists.
This would suggest that the leukotrienes C^, D^ and E^ are acting 
at the same receptor, which is further substantiated by the 
observed antagonism by FPL 55712 of the three leukotrienes.
The differential tissue response time observed between
LTC.-induced contractions and LTD. or LTE.-induced contractions 
4 4 4
could be excused by membrane transport effects. That is, if the 
receptor is intracellular and the leukotrienes must translate the 
cell membrane by a passive diffusion process, it is conceivable 
that the most polar leukotriene LTC^ is transported more slowly 
through the lipid bilayer, resulting in a slower response time. 
This would also explain the difficulty in washing out the 
response to LTC^ as the reverse diffusion process would be 
equally as slow. It does not, however, explain why the LTD^, or 
LTE^-induced responses should be transient whereas those to LTC^ 
are maintained. Furthermore, a single receptor theory does not
-49-
explain the inconsistency of FPL antagonism in this tissue, being 
apparently a competitive antagonist of LTD^ but a non-competitive 
antagonist of LTC^. The partial antagonism by LTE^ of LTC^, also 
appeared more competitive than that against LTD^, which again is 
inconsistent with a single receptor mechanism but is not a strong 
enough discrepancy to evoke multiple receptor mechanisms in this 
tissue.
The guinea-pig lung parenchymal preparation showed the same rank
order of potency as on the ileum viz LTC. > LTD. > LTE.. The
  4 4 4
differential efficacy again allowed the least efficacious
compounds to be tested as partial agonists. LTD^ and LTE^ were
both found to antagonise the contractions induced by LTC^ in the
presence of enzyme inhibitors which suggested a homogenous
receptor population akin to the guinea-pig ileum system.
However, in contrast to the ileum, the LTC. and LTD. induced
4 4
contractions in the parenchymal preparation were not antagonised
by the reference antagonist FPL 55712, which implies a distinct
receptor type on the guinea-pig lung parenchyma.
In contrast to the previous systems, the ferret spleen showed a 
rank order of potency LTC^ = LTD^ »  LTE^. LTE^ again behaved as 
a partial agonist, antagonising contractions induced by both LTC^ 
and LTD^ on this tissue. In similarity to the guinea-pig lung, 
FPL 55712 failed to antagonise the leukotriene-induced 
contractions of this tissue. These results clearly indicate a 
homogenous population of receptors on the ferret spleen system.
-50-
The ferret spleen receptor system is similar to that in the 
guinea-pig lung since both systems are FPL 55712 resistant, 
although the rank order of potencies for the leukotrienes 
suggests that the receptors are non-identical. If the receptors 
in guinea-pig lung and ferret spleen were identical then 
comparing EC^^’s one would expect the lung strip to have a
—8
greater receptor reserve (LTC^ E C ^  LUNG = (4.2 ± 1.5) x 10 M; 
EC^-q SPLEEN = (2.8 ± 0.7) x 10 ^ M ) . This is consistent with the 
partial agonist LTE^ having greater efficacy in the lung compared 
with the spleen, but it is inconsistent with the partial agonist 
LTD^ on lung exhibiting full agonist effects on a system with a 
lower receptor reserve ie ferret spleen.
Thus it is proposed that the guinea-pig ileum test system 
contains a homogenous population of receptors characterised by a 
rank order of potency LTC^ > LTD^ > LTE^ and is antagonised by 
FPL 55712. This shall be termed the LT^ receptor. Furthermore, 
the guinea-pig lung test system contains a distinct homogenous 
receptor population termed LT^* characterised by a rank order of 
potency LTC^ > LTD^ > LTE^ and is unaffected by the antagonist 
FPL 55712. Finally the ferret spleen preparation contains a 
third type of receptor, LT^, characterised by a rank order of 
potency LTC. = LTD. »  LTE. and is also unaffected by FPL 55712.
-51-
CHAPTER 2
Characterisation of the agonist pharmacophoric groups
INTRODUCTION
Due to the structural complexity of leukotrienes a clear 
indication of the ligand pharmacophore would only result from the 
synthesis of a considerable number of carefully designed 
analogues. In the first instance the design and synthesis of 
analogues was limited to structures which could be constructed 
relatively simply from the synthetic fragments used in the 
synthesis of leukotrienes (Chapter 1). Furthermore, it was 
decided to critically focus attention on the functionally less 
complicated leukotrienes LTD^ and LTE^,.
A  "Peptide Analogues"
The first approach was to investigate the pharmacophoric nature 
of the peptide region of leukotrienes. Such analogues were 
prepared by reacting LTA^-methyl ester with a thiol followed by 
hydrolysis of protecting groups in a manner analogous to the 
synthesis of natural leukotrienes. This gave a series of 
compounds differing from the parent molecule only in the nature 
of the substituent attached to the sulphur at C-6. The analogues 
in this series can be likened to LTE^ and are shown alongside the 
parent in Figure. 33.
-52-
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SYNTHESIS
Thus Analogue 1 (A-l) was prepared by the reaction of methane 
thiol with LTA^-Me in basic media followed by subsequent 
hydrolysis of the C-l ester.
Cysteamine hydrochloride was protected as the trifluoroacetyl
derivative prior to reaction with LTA^-Me. Deprotection in the
usual manner afforded A-2. Similarly A-3 and A-4 were prepared
from methyl 3-mercaptopropionoate and 2-mercaptoethanol
respectively. l-mercaptobutan-3-one was prepared from the
addition of hydrogen sulphide to methylvinylketone by the method 
103
of Ross and subsequently reacted with LTA^,-Me to yield A-5.
In all cases the resulting analogues were purified by a 
combination of reverse-phase preparative thin-layer 
chromatography (RP-ptlc) and reverse-phase high pressure liquid 
chromatography (RP-HPLC).
RESULTS
The biological activities of analogues A-l - A-5 are given in 
Figure 34 and the dose-response curves are included at the end of 
the chapter. The results are given as means of n = 2-4 
experiments and for this reason statistical analysis is not 
possible.
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KEY
Note
FA = Full agonist; Analogue capable of eliciting 
maximal, or near-maximal tissue contraction 
compared to LTD^ or LTC^.
WA = Weak agonist; Analogue which does not elicit
>50% LTD, maximal contraction at 10 
4
concentration, and is devoid of antagonistic 
activity.
PA = Partial agonist; Analogue which effects less
than maximal tissue contraction and antagonises 
reference agonist responses.
ANT = Antagonist.
I = Inactive
Unless otherwise stated, LTD^ was used as the reference 
agonist (control)
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Analogue R Guinea-pig Guinea-pig Ferret Spleen
Ileum Lung
LTE,
4
c h 2c h (n h 2)c o 2h PA PA PA
1
CH3
WA FA 60 I
2 CH2CH2NH2
*
1,1 WA -
3 CH2CH2C02H FA 1.7 FA 33 ANT 7.1
4 CH2CH2OH FA 15 FA 40 I
5 CH2CH2COCH3 FA 180 FA 53 I
* LTC, Control 
4
Fig. 34
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i) Guinea-pig ileum
With comparison to LTE^, it can be seen that removal of the 
carboxyl group (A-2) and further removal of the aminomethyl group 
(A-l) result in virtually complete loss of agonistic activity on 
this tissue. Furthermore, as A-l and A-2 in combination with 
LTD^, or LTC^ , do not affect the agonist responses, it can be 
assumed that they have little or no affinity for the leukotriene 
receptors in this system.
This implies that the carboxyl group of LTE^ is a pharmacophoric
group, essential for the affinity and activity of the molecule.
This is further substantiated by the effect of A-3 on the
guinea-pig ileum. A-3 differs from LTE^, only in that it lacks
the o(-amino functionality; however, it is a highly potent
agonist, more so than LTE^, itself and it also achieved maximal
tissue contraction relative to LTD..
4
Taken together these results imply a redundancy of the Of-amino 
group of LTE^ in the agonistic pharmacophore and the necessity of 
the 0(-carboxyl group.
Replacing the propionic acid substituent of A-3 with an ethyl 
alcohol residue (A-4) results in a 10-fold loss of activity 
compared with a 100-fold loss of activity for the carbonyl 
derivative A-5. This could imply that the nature of the 
pharmacophoric interaction is hydrogen bonding with hydrogen
-57-
donation from the ligand. If this were so then a carboxyl group
would interact best in its unionised form which would be favoured
by a higher pKa. Indeed this is seen to be the case comparing
LTE^. (pKa = 2.1) and A-3 (pKa = 4.5). Removal of the amino
functionality to a carboxyl group raises the pKa of the acid
thus increasing the proportion of unionised carboxylate groups
and favours interaction by hydrogen bonding rather than by
coulombic effects. As A-3 was indeed observed to be more potent
and efficacious than LTE. this could well be the mode of
4
interaction of the carboxyl pharmacophoric group. Furthermore, 
comparing the aminoethyl derivative, A-2 with the hydroxyethyl 
analogue, A-4, it is apparant that the stronger hydrogen bonding 
alcohol confers considerably greater activity to the molecule, 
supporting the proposed hydrogen bonding interaction of this site 
with the receptor.
ii) Guinea-pig lung
This system appears to be extremely accommodating for this series
of analogues; with the possible exception of A-2 they were all
full agonists of similar potency. It would seem that the nature
of the substituent attached to the sulphur is not crucial to
activity although an acidic function (e.g. A-3) may be slightly
favoured. The general trend of results, however, is similar to
that on the ileum; indeed the rank order of potencies is the
same. A-3 > LTE. > A-4 > A-5 > A-l > A-2.
4
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iii) Ferret spleen
This preparation is in direct contrast to that of the guinea-pig 
lung strip; all analogues were inactive with the exception of 
A-3. As LTE^ itself was a partial agonist in this system it is 
not surprising that A-3 showed a similar profile of activity. 
Whereas in the guinea-pig ileum the acidic analogue A-3 exhibited 
the greatest activity, it appears that the carboxyl group is 
essential for activity on the ferret spleen.
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B "Tail Analogues"
Another approach was to investigate the pharmacophoric nature of 
the lipophilic ’tail1 region of LTD^. For this purpose a number 
of LTA^-Me analogues were prepared by Wittig condensation of 
alkyl ylides with either the 7-C aldehyde (1) or the 11-C 
intermediate (VII). The resulting LTA^-Me analogues were 
condensed with protected cysteinyl glycine and saponified to give 
the tail-modified analogues of LTD^ shown in Fig. 35.
OH OH
LTD
4
Analogue 6
OH OH
Analogue 7 Analogue 8
Analogue 9
Fig. 35
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SYNTHESIS
Thus n-dodecyltriphenylphosphorane, prepared in the usual manner 
at -78°C, condensed with the 7-C aldehyde (1) to yield methyl 
5 (S),6(S)-oxido-7(Z)-nonadecenoate (XXIV) with exclusively cis 
double bond geometry. Methyl 5(S),6(S)-oxido-7(E),9(E),11(Z)- 
heptadecatrienoate (XXV) and methyl 5(S),6(S)-oxido-7(E),
9(E),11(Z)-tridecatrienoate (XXVI) were similarly prepared by 
condensation of the ylides from n-hexyltriphenylphosphorane and 
ethyltriphenylphosphorane with the 11-C intermediate (VII) 
respectively (Fig. 36).
XXIV
XXV
XXVI
Fig. 36
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The lack of extended conjugation in epoxide (XXIV) compared with 
the natural triene unit of LTA^ confers considerably greater 
stability to the molecule. Indeed, as a result of the forcing 
conditions required to effect opening of the epoxide, a mixture 
of isomers resulting from Sn2 attack at both the C-6 and C-5 
positions was obtained (A-6 and A-7 respectively). Epoxides 
(XXV) and (XXVI), however, reacted smoothly with the thiol as 
expected, to give the corresponding addition products A-8 and A-9 
upon deprotection.
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RESULTS
The functional activity of analogues A-6 to A-9 are summarised in 
Figure 37 and the dose-response curves included at the end of the 
chapter.
Analogue Guinea-Pig
Ileum
LTD, FA 1.0
4
A-6 FA 6.0*
A-7 FA 10*
A-8 FA 320
A-9 FA 8000
* LTC, Control 
4
Fig. 37
i) Guinea-pig ileum
The guinea-pig ileum system showed remarkable tolerance to 
reduction of the 9-, 11- and 14- double bonds as indicated by the
Guinea-Pig Ferret Spleen
Lung
FA 1.0 FA 1.0
FA 24 FA 12
WA I
FA 20 
FA 85
-63-
virtual equipotency of A-6 to the parent LTD^. Even more 
surprising was the good agonistic activity displayed by the 
structural isomer A-7 implying an equally efficacious receptor 
occupancy. However, retention of the conjugated triene moiety 
and shortening the tail length resulted in a dramatic loss of 
activity for the analogue A-8 and virtual inactivity for the 
analogue A-9.
These results imply that the guinea-pig ileum system requires a 
substantial hydrophobic moiety although a high degree of 
unsaturation is not required in the agonist pharmacophore.
ii) Guinea-pig lung
The guinea-pig lung strip was slightly more sensitive to the loss 
of unsaturation than the ileum, as shown by the hexahydro- 
analogue A-6. The necessity of the correct substitution and 
orientation was furthermore displayed by the weak activity of 
A-7, the structural isomer of A-6. Shortening of the tail, 
however, with retention of the triene system retained good 
activity in the guinea-pig lung strip at length (shown by 
A-8) with some decline in activity at length (A-9).
Thus in contrast to the ileum the guinea-pig lung strip system is 
tolerant to tail shortening and tail saturation but requires the 
thiopeptidyl substitution at C-6 for good agonistic activity.
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iii) Ferret spleen
The ferret spleen was comparable to the guinea-pig lung strip 
results for the compounds A-6 and A-7. These analogues display 
the tolerance of the ferret spleen to loss of unsaturation in the 
tail but the dependance for activity on the correct substitution 
pattern.
C "Alkanoyl Analogues11
It was demonstrated in the first section of this chapter that a 
pharmacophoric carboxyl group was present in the peptide region 
of leukotrienes. To further evaluate the nature of this 
pharmacophoric group in the various receptor systems and to 
achieve a better understanding of the receptors' requirements in 
this region, it was decided to synthesise a homologous series of 
analogues to determine the optimal position for the carboxyl 
function within the receptor pharmacophore.
SYNTHESIS
Thus, methyl mercaptoacetate, methyl 3-mercaptopropionate 
(previously described), methyl 4-mercaptobutanoate, methyl 
5-mercaptopentanoate and methyl 7-mercaptoheptanoate were reacted 
with LTA^-Me in the usual manner and subsequently deprotected to 
afford the analogues A-10, A-3, A-ll, A-12 and A-13 respectively 
(Fig. 38). The biological results are summarised in Fig. 39 and 
the dose-response curves included at the end of the chapter.
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:OaH
Analogue 10 Analogue 3
Analogue 11 Analogue 12'
OH
•COaH
Analogue 13
Fig. 38
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RESULTS
OH
Analogue n Guinea-Pig Guinea-Pig Ferret Spleen
Ileum Lung
A-10 1 FA 6.3 FA 2.9 FA 2.9
A-3 2 FA 1.7 FA 33 ANT 7.1
A-ll 3 PA,PA* FA 5.7 ANT 8.0
A - 12 4 FA 13 FA 3.7 PA
A-13 6 FA 800 FA 60 I
* LTC. Control 
4
Fig. 39
i) Guinea-pig ileum
On the guinea-pig ileum good agonism is observed for the short
(n = 1-4) alkanoyl analogues with apparent loss of activity when
n = 6 (A-13). Interestingly, A-ll only achieved approximately
60% of the maximal contraction induced by LTD^ on this tissue and
at a concentration of 10 significantly antagonised both LTD^
and LTC. induced contractions, which is similar to the results 
4
observed with LTE. on this tissue.
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Thus, the agonistic pharmacophore on the guinea-pig ileum accepts 
a range of structural variations in this region. However, when 
n = 3 (A-ll), the ligand begins to induce binding to the ground 
state or antagonistic conformation of the receptor as well as the 
agonistic state, which gives rise to the observed partial 
agonistic effect. This indicates that there is a narrow window 
of antagonistic activity in this range of analogues and perhaps 
by slight structural modification it may be possible to optimise 
this effect.
ii) Guinea-pig lung
This series of analogues also displayed good agonistic activity 
on the guinea-pig lung parenchymal preparation, with perhaps 
slight loss of activity at n = 2 and n = 6. This depression of 
agonism may be likened to that for n = 3 and n = 6 on the 
guinea-pig ileum, although the apparent sensitivity of the lung 
to agonistic effects may mask any slight antagonistic activity 
which would otherwise be observed.
iii) Ferret spleen
The ferret spleen preparation shows a remarkable profile of 
activity for this series of analogues. A-10 (n=l) is a full 
agonist of equal potency to LTD^. A-3 and A-ll (n=2 and 3 
respectively) behave, like LTE^, as antagonists and when n=4 
(A-12) the antagonistic activity weakens again and some agonistic
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activity returns to the molecule. A-13 (n=6) is inactive in this 
system.
Thus the ferret spleen follows the same trend as the guinea-pig 
ileum (and possibly the guinea-pig lung strip) with agonistic 
activity peaking at n = 1 and 4, sandwiching a region of 
antagonistic activity. The marked difference, of course, is the 
ease of antagonism on the ferret spleen.
DISCUSSION
It has been shown that the guinea-pig ileum agonist pharmacophore 
requires a proton-donating group, especially a protonated 
carboxyl, in the peptide region of the analogue. Ideally the 
carboxyl group should be separated from the sulphur atom by one 
or two methylene groups; partial agonism being observed when the 
separation is increased to three methylene groups. The 
hydrophobic tail may be considerably saturated with retention of 
good agonistic activity, however, the natural length must be 
maintained.
The guinea-pig lung strip agonist pharmacophore defies analysis. 
It appears that the peptide moiety of leukotrienes is not 
necessary for full agonistic activity and furthermore that the 
hydrophobic tail may be considerably saturated or shortened with 
little effect on activity.
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The ferret spleen agonist pharmacophore is more clearly defined, 
requiring either the natural LTD^ or LTC^ peptide for full 
agonistic effect or the thioacetyl derivative, as in A-10. For 
the natural peptide of LTD^, the tail accepted considerable 
saturation without dramatic loss in activity, again implying a 
redundancy of the 9-, 11- and 14- double bonds. In contrast to 
the previously described systems, the ferret spleen is readily 
antagonised, indeed the difference between the full agonist A-10 
on this system and the antagonist A-3 is merely one methylene 
group.
Thus although the three test systems behave differently to one 
another, the underlying trends are similar. It is apparent that 
the agonist pharmacophore may be simplified to the thioacetyl 
analogue A-10, which suggests that the pharmacophoric interaction 
between the peptide carboxyl and the receptor is quite close to 
the sulphur atom in the agonistic conformation of the receptor. 
Fig. 40 shows a possible conformation of the peptide of LTD^ 
complying with the structural restrictions imposed by A-10. A 
proposed mechanism of receptor activation, therefore, could be 
the attraction of a distant group in the receptor site by 
hydrogen bonding to the hydroxyl group leading to the formation 
of the agonist complex (Fig. 41).
-70-
HsNt
A i ^ 1
S t
0
A-10 LTD OVERLAP
Fig. 40
The polar group in the receptor responsible for co-ordination 
with the carboxyl group of the ligand may be, for example, the 
hydroxyl of a serine residue. To make this residue more reactive 
to hydrogen bonding it could be enclosed in a lipophilic 'pocket' 
making 'solvation' by the ligand an energetically favourable 
process.
Ground-state receptor
OH
HaM,
Agonist complex
Fig. 41
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This model would also serve to explain how, by extending the 
carboxyl group by one or two methylene units, a region of 
antagonistic activity is obtained. It can be seen that binding 
to the ground state receptor could easily be achieved by A-ll, 
for example, as was observed in the ferret spleen test system 
(Fig. 42); or equally, a different conformation may be adopted, 
leading to agonistic activity as was observed in the guinea-pig 
lung test system (Fig. 43).
A combination of these two conformations would lead to partial 
agonist activity, as was observed on the guinea-pig ileum.
This model, therefore, goes a long way towards explaining the 
observed results for the analogues encountered in this chapter. 
The following chapter will test the model by using it as a basis 
for the design of leukotriene antagonists.
Antagonist Agonist
Fig. 42 Fig. 43
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DOSE-RESPONSE CURVES
KEY
O  = LTD. Control
4
0  = LTD^ in presence of 10 ^ M  test drug
o  = LTC. Control
4
+  = LTC^ in presence of 10 ^ M  test drug
^  = Test drug alone
-73-
% 
Ma
xi
mu
m 
LTD
,, 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 1 on Guinea-Pig Ileum
o— o— ©— o
60 -
• •
til Vi>   W  \1> Vi/ vt/ WJR  SK JK JK 7R
10-12 10-11 10_1° 10-9 10-8 10-7 10-6 10-5
Concentration (M)
Analogue 1 on Guinea-Pig Lung
100-
10-1° 10'9 10-8 10"7 10-6 10-5
Concentration (Ml
-74-
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 1 on Ferret Spleen
1 0 0 -
10-1° 10-9 10-B 10-7 10-6 10-5
Concentration (M)
Analogue 2 on Guinea-Pig Ileum
O O
10-12 10-11 10-1O 10-9 10-8 10-7  10-6
Concentration (M)
-75-
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
X 
Ma
xi
mu
m 
LT
C4 
Re
sp
on
se
Analogue 2 on Guinea-Pig Ileum
120 -
100-
40-
10-12 iQ-ii 10 io 10-9 10“8 10-7 10-6
Concentration (M)
Analogue 2 on Guinea-Pig Lung
•  •
20 -
10 -!° 10-9 10-8 iq -7  IQ-6 10-5
Concentration (M)
-76-
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 3 on Guinea-Pig Ileum
10-12 iQ-ii lo io IQ-9 1O-0 10-7 10-6
Concentration |M)
Analogue 3 on Guinea-Pig Lung
40-
10-1° IQ-9 IQ-0 i q -7 i q -6 i q -5
Concentration (M)
-77-
3! 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 3 on Ferret Spleen
80-
20 -
Concentration (M)
i
Analogue 4 on Guinea-Pig Ileum
40-
20-
Concentration (M)
-78-
X 
Ma
xi
mu
m 
LT
04 
Re
sp
on
se
 
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 4 on Guinea-Pig Lung
1 0 0 -
80-
20 -
lO"10 10-9 10“B 10"7 10-6 10-5
Concentration (M)
Analogue 4 on Ferret Spleen
80-
60-
Concentration (M)
-79-
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 5 on Guinea-Pig Ileum
100 - 
80- /
60- /  f/
40
20-
/
/
/
/>
/ /
/
0 [ x---------- x -Xr
ox  X  i
L.
lO"10 10"9 10-B 10"7 iO-6
Concentration (M)
Analogue 5 on Guinea-Pig Lung
100- p
/
/
80- /
6°l x "  X
40 r /  . X
20-  -°'
. *-
Or
10-1° 10-9 10-B 10-7 10-6 IQ-5
Concentration (M)
-80-
Analogue 5 on Ferret Spleen
120
100<uto
cz
CD
CD.
CO
03
CO 80-
CD
60-I—  ___I
40-
20 -
Concentration (H)
Analogue 6 on Guinea-Pig Ileum
120-
100 -03CO
CZ
CD
CD.
CO
CD
cn 80-
C_J
60-
40-
20 -
10-io 10-9  10-8 10“7 10-6 10-5
Concentration (M)
-81-
5! 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 6 on Guinea-Pig Lung
10 0 -
20 -
lO"10 10-9 10-8 iO-7 10-B 10-5
Concentration (M)
Analogue 6 on Ferret Spleen
40 L
10“ 1Q iO-9 10~8 10-7 10-6 10-5
Concentration (M)
-82-
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
Z 
Ma
xi
mu
m 
LT
C4 
Re
sp
on
se
Analogue 7 on Guinea-Pig Ileum
80-
10-1° io-9 10-8 10-7 IO-6 10"5
Concentration (M)
Analogue 7 on Guinea-Pig Lung
20 -
10-i° io-9 IO"8 IO-7 10"6 10-5
Concentration (M)
-83-
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 7 on Ferret Spleen
10-1° 10-9 10"8 10-7 IQ-6 IQ-5
Concentration (M)
Analogue 8 on Guinea-Pig Ileum
i00L
60-
40-
20 -
1Q-10 IQ-9 i q -B i q -7 IQ-6 i q -5
Concentration (Ml
-84-
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 8 on Guinea-Pig Lung
20 -
10-io 10-s 10-B iq-7 iq-6 iq-5
Concentration (M)
Analogue 9 on Guinea-Pig Ileum
80-
60
40-
20 -
lO-io i q -9 IQ-8 i q -7 i q -6 i q -5
Concentration (M)
-85-
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 9 on Guinea-Pig Lung
40-
20 -
lO'10 IO-9 10“B IO-7 iO-6 IO-5
Concentration (M)
Analogue 10 on Guinea-Pig Ileum
100 i o-
20 -
10-12 10-11 10-iO 10-9 10-8 10-7 10-6
Concentration (M)
-86-
Analogue 10 on Guinea-Pig Lung
cd
COcz
o
CL
CO
CD
□C
CD
!—  
__I
E
ID
E
• r— I
X
CD
s:
40-
20 -
10-12 io-11 lO-10 10"9 10'8 10-7 10"6 10“5
Concentration (Ml
Analogue 10 on Ferret Spleen
CD
CO
cr
o
CL
CO
CD
CO
''T
CD
Concentration (M)
-87-
Ma
xi
mu
m 
LT
C4 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue li on Guinea-Pig Ileum
100-
80-
60-
40-
i
20-
0-
\
\
O---,
/
/
/
/
/
/
-ae- -w
IQ-12 10-11 IQ-IO lQ-9 IQ-0 iq-7 IQ-6
Concentration (M)
r
1004-
I
I
80-
60-
4
i
i
20 f
!
0r
Analogue 11 on Guinea-Pig Ileum
.O'
o — o — o
/
/
o
/
♦--- ♦—-------♦ ♦/ V
o *
/
/
/
J
10-12 10-11 10-10 10-9 10-8 10-7 10-6
Concentration (M)
-88-
*
•
Analogue 11 on Guinea-Pig Lung
100-
as 
in 
cz 
o  cx 
cn
03
d
80-
60-
40-
20 -
* — * — *
10-12 JO"11 lO-10 10-9 10-8 10-7 10"6
Concentration (M)
Analogue 11 on Ferret Spleen
100 -
03
incz
a
80-
CLin
03
cz 60-
CD
I—  
__I
EZD
EE:
>t— i
40 F
20 -
Concentration (H)
-89-
I 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 12 on Guinea-Pig Ileum
80
60-
10-1° jg-9 10-8 10-7 10-6
Concentration (M)
10-
Analogue 12 on Guinea-Pig Lung
60-
60 r
 1------- '--  1-— i ---- - ----- -----
10"12 10-11 10~10 10-9 10"8 10"7 10”6 10"5 
Concentration (M)
-90-
% 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 12 on Ferret Spleen
80-
lO-io 10-9 10-a 10"7 10_a 10"5
Concentration (M)
Analogue 13 on Guinea-Pig Ileum
O  — O
O--
8 0 L
40 L
20 -
10-12 10-11 IQ-IO 10-9 10-8 10-7 10-6 10-5
Concentration (M)
-91-
X 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
 
I 
Ma
xi
mu
m 
LT
D4 
Re
sp
on
se
Analogue 13 on Guinea-Pig Lung
100 -
:r=is— 8— a— i
10-12 j q - 11 io-10 10“9 10-B 10-7 10"6 10-5
Concentration (M)
Analogue 13 on Ferret Spleen
40L
20 -
  O
10-1° 10"9 10-8 10-7 10"6 10-5
Concentration (M)
-92-
CHAPTER 3
Studies towards leukotriene antagonists
INTRODUCTION
The model of leukotriene receptor activation proposed in Chapter 
2 involved the attraction of a hydrophilic moiety buried in a
lipophilic pocket. It was discovered that simple
CO-thioalkylcarboxylic acids display good antagonistic activity 
in the ferret spleen test system yet retain potent agonism in the 
guinea-pig ileum and lung preparations. In an attempt to retain 
receptor affinity and induce binding solely to the ground state 
receptor it was decided to introduce alkyl substitutents of to the 
carboxylic acid which may interact with the hydrophobic pocket 
and achieve the desired affect. A  second approach was to 
restrict the conformation of the acidic ’peptide’ substituent by 
incorporating the carboxylic acid on a thiophenyl leukotriene 
derivative. In this way the position of the carboxyl group is 
limited to a distinct region of space with regards to the sulphur 
atom and it may be possible to restrict binding to the ground 
state receptors.
A ALKYLATION STUDIES
Analogues A-10 and A-3 were chosen as the basis for the
alkylation studies because of their good affinities on all
three biological test systems. It was decided to initially
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restrict the study to methylation of to the carboxyl groups, 
giving a series of six compounds as shown in Fig. 44.
SYNTHESIS
The analogues were prepared in the usual manner of reacting 
the thiol with LTA^-Me followed by deprotection. The thiols 
were either commercially available or were prepared from the 
corresponding halides by treatment with sodium 
hydrogensulphide. Where the halides were not available they 
were prepared from the corresponding alcohols by treatement 
with thionyl chloride. Esterification of the free acids 
prior to addition to LTA^-Me was effected by treatment with 
diazomethane. The diastereomers A-14 and A-15 were 
separated at the protected stage but their absolute 
structures were not assigned. The biological results are 
summarised in Figure 45 and the dose-response curves 
included at the end of the chapter.
-94-
OH OH OH
Analogue 10 Analogue 14,15 Analogue 16
OH OH OH
Analogue 3 Analogue 17,18 Analogue 19
Fig. 44
RESULTS
Analogue
A-10
A-14
A-15
A-16
Guinea-pig 
Ileum 
FA 6.3 
FA 48 
FA 3.7 
FA 80*
Guinea-pig 
Lung 
FA 2.9 
FA 7.0 
FA 11 
FA 100
Ferret Spleen
FA 2.9 
PA 5.8 
PA 7.1 
PA 6.1
A-3 
A-17 
A - 18 
A - 19
FA 1.7 
PA/WA 
FA 58 
FA 3405
FA 33 
FA 81 
FA 19 
WA
ANT 7.1 
ANT 7.0 
ANT 6.5 
ANT 5.4
* LTC, Control 
4
Fig. 45
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i) Guinea-pig ileum
On the guinea-pig ileum system, one of the monomethyl 
derivatives, A-15, retained the full agonist potency of its 
parent, A-10. The epimer, A-14, however, was at least an order 
of magnitude less potent and the dimethyl derivative, A-16, also 
displayed diminished agonistic activity. The methyl analogues of 
A-3 showed a similar profile of activity, with the S isomer,
A-18, retaining considerably more agonistic activity than the R 
isomer, A-17. The dimethyl derivative A-19 was similarly less 
effective than the S-monomethyl analogue, A-18.
It can be seen from the dose-response curve of A-17 on guinea-pig 
ileum that the R-monomethyl derivative may have been exhibiting a 
degree of antagonism here, although the effect is masked by the 
residual agonistic activity of the molecule.
ii) Guinea-pig lung
Similar trends were observed for the analogues on this tissue as 
on the guinea-pig ileum. That is, the dimethyl analogues A-16 
and A-19 were less potent than the monomethyl derivatives and for 
the A-3 type analogues A-17 and A-18, the S isomer, A-18 retained 
the greatest agonistic activity. Unfortunately no hint of 
antagonistic activity was observed here.
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iii) Ferret spleen
On this tissue, antagonistic activity was observed for the whole 
series of ’methyl1 analogues. Although the ‘A-10’ series 
retained some agonistic behaviour, good antagonism was observed 
with one of the mono-methyl isomers, A-15. Interestingly, this 
is the same isomer that retained full agonistic potency on the 
ileum test system. The epimer, A-14, and the dimethyl analogue 
A-16, were an order of magnitude weaker antagonists which also 
reflected their agonistic profile on the guinea-pig ileum. The 
introduction of R and j3 methyl groups on A-3 was tolerated by the 
ferret spleen, although no improvement in antagonistic activity 
was observed. The dimethyl derivative A-19, however, was a 
considerably weaker antagonist than either of the monomethyl 
derivatives A-17, A-18 or the parent, A-3.
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The second approach of structural manipulation to confer 
antagonistic properties on leukotriene analogues was to 
restrain the carboxyl group by the incorporation of an 
aromatic ring in the 'peptide* moiety. The analogues 
synthesised are shown in Figure 45 and the biological 
results in Figure 46.
SYNTHESIS
Ortho, meta and para-methyl mercaptobenzoates were reacted
with LTA^-methyl ester followed by deprotection in the usual
manner to afford analogues A-20, A-21 and A-22 respectively.
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The thiophenols were prepared by the method of Wiley , 
from the corresponding aminobenzoic acids by diazotisation 
and elimination with ethyl potassium xanthate. Hydrolysis 
of the xanthate esters yielded the thiols, the free carboxyl 
groups being esterified prior to reaction with LTA^-Me.
OH OH
Analogue 20 Analogue 21
OH
Analogue 22 
Fig. 45
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RESULTS
O H
C 0 2H
Analogue Substitution Guinea-pig Guiena-Pig
Ileum Lung
20 ORTHO FA 130 WA
21 META FA 19 FA 10
22 PARA ANT 8.0* ANT 5.8*
* LTC, Control 
4
Fig 46
-99-
Ferret
Spleen
PA >6.5 
ANT >7.0 
ANT 6.5*
i) Guinea-pig ileum
On the guinea-pig ileum this series of analogues show a 
remarkable range of activity from good full agonism to 
antagonism. The receptor requirements are clearly defined as is 
shown by the difference between the meta-analogue A-21, being a 
good full agonist, and the para-analogue A-22, which is a potent 
antagonist.
ii) Guinea-pig lung
A similar trend is observed in the guinea-pig lung as on the 
ileum, with the meta-substituted analogue A-21 displaying the 
greatest agonism and the para-substituted analogue A-22 being an 
antagonist.
iii) Ferret spleen
The ferret spleen shows some weak agonism for the ortho analogue 
A-20 but the meta- and para- analogues A-21 and A-22 respectively 
are good antagonists.
DISCUSSION
The alkyl-substituted series of analogues, A-14 - A-18, showed 
little of the desired increase in antagonistic activity. In the 
ferret spleen partial agonism was observed for the methyl series
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of A - 10 and in the guinea-pig ileum the R-monomethyl derivative, 
A-17 showed weak partial agonism. With these exceptions the 
series generally reflected the activity of the parent molecules 
with one of the monomethyl optical isomers showing greater 
activity than the other and the dimethyl derivatives having the 
weakest activity. Although the desired profile of activity was 
not observed with this series it is interesting to note that the 
alkyl substituents were generally tolerated by the receptors 
implying that the initial premise was not completely wrong.
The mercaptobenzoic acid series of analogues, A-20 - A-22, 
possessed a wide range of activities from good full agonism to 
strong antagonism in the three test systems.
The ortho- and meta-analogues, A-20 and A-21, show a profile of 
activity reminiscent of the alkanoyl analogue A-3, being agonists 
on the guinea-pig ileum and lung, and displaying antagonistic 
activity on the ferret spleen. The para-analogue, A-22, however, 
has the desired spectrum of activity, being an antagonist in all 
three systems.
These results fit nicely into the proposed model of leukotriene 
receptor activation discussed in Chapter 2. Fig. 47 shows a 
comparison of the ’peptide* region of A-20 and A-21 with A-3; it 
is not too difficult to imagine these compounds showing similar 
profiles of activity. The para-analogue, A-22, was shown to be 
an antagonist in all three systems; being devoid of agonistic
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activity, it must bind solely to the ground state of the 
receptors. The proposed model is consistent with the observed 
phenomena as shown in Fig. 48.
‘0 — H
.0— H
0
.0— H
0
A-20 A-21 A-3
Fig. 47
X 0 2H
o h  r
Fig. 48
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It is remarkable that such a small structural change such as 
para-substitution compared to meta-substitution resulted in 
completely opposite biological effects in guinea-pig tissues. 
This clearly demonstrates the strict structural requirements of 
the receptor in this region of the pharmacophore and serves to 
further reinforce the belief that the observed phenomena are 
indeed mediated by receptor interactions, as physiological 
agonism-antagonism would tend to be less specific.
The observed difference in effectiveness of A-22 to antagonise 
LTC^ induced contractions in the three test systems as shown by 
the differing pIC. values, is further evidence for the receptorD
types being different. This is consistant with the receptor 
classification discussed in chapter 1 which identified LT1 
receptors on guinea-pig ileum, LT2 receptors in guinea-pig lung 
and LT3 receptors in the ferret spleen. It can be seen from 
Fig. 46 that A-22 is approximately an order of magnitude more 
effective on LT1 than on LT3, and approximately an order of 
magnitude more effective on LT3 than on the LT2 receptor.
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DOSE-RESPONSE CURVES
KEY
O  = Control
#  = LTD^ in presence of 10 ^ M test drug
O  = LTC^ Control
+  = LTC^ in presence of 10 ^ M test drug
= Test drug alone
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CONCLUSION
CONCLUSION
Chapter 1 described the synthesis and biological evaluation of 
the leukotrienes: the natural agonists of the receptors under 
discussion. This is a necessary part of drug development as they 
are required as internal controls for the comparison of agonists 
and are obviously required to show the action of antagonists.
The intermediates synthesised for the preparation of leukotrienes 
were then utilised in the preparation of leukotriene analogues to 
probe the receptor agonist and antagonist pharmacophores.
Chapter 2, dealt with the simple modifications of the leukotriene 
structure aimed at identifying pharmacophoric groups. The most 
crucial pharmacophoric group was found to be the peptidyl 
carboxyl group and it was further discovered that the agonist 
pharmacophore could be simplified to A-10.
CH
CO2H
AGONIST 
ANALOGUE 10
This greatly simplified molecule retained all the potency and 
activity of the natural leukotrienes LTD^ and LTC^ and was the 
starting point for the development of antagonists.
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Chapter 3 details two areas from which the design of antagonists 
was approached. The introduction of hydrophobic moieties in the 
peptidyl region was generally tolerated but did not significantly 
affect the activity profiles. However, when rigidity combined 
with displacement of a pharmacophoric group was introduced into 
the molecule the desired profile of activity was achieved. Thus 
by ’locking1 the pharmacophoric carboxyl moiety at a site 
distinct from the known position of the agonist pharmacophoric 
binding site it was possible to confer binding solely to the 
ground state receptor.
A leukotriene antagonist has been designed which was effective on 
three different classes of leukotriene receptors. In comparison 
with FPL55712, which was only active on one of these receptor 
systems, it is apparent that this is a major breakthrough in the 
field of leukotriene research.
Further structure-activity studies are currently progressing in 
our laboratories in an attempt to improve the binding affinity 
and increase the stability of A-22, however this is not the 
subject of this thesis.
OH
ANTAGONIST
ANALOGUE 22
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Thus in conclusion, it has been shown that by applying receptor 
theory and concepts of molecular recognition it has been possible 
to design an antagonist based on the chemical structure of an 
agonist. It has yet to be shown that a compound with the profile 
of activity of A-22 is therapeutically beneficial but compounds 
of this type may play a major role in alleviating the symptoms of 
asthma and other allergic disorders involving leukotrienes.
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EXPERIMENTAL
Experimental Notes
Solvents
Dichloromethane was distilled from phosphorous pentoxide and
o
stored under an inert atmosphere over 3A molecular sieves.
Hexamethylphosphoramide was dried by stirring with powdered
calcium hydride overnight followed by distillation under reduced
o
pressure and stored under an inert atmosphere over 4A molecular 
sieves.
Methanol was distilled from sodium methoxide and stored under an
o
inert atmosphere over 3A molecular sieves.
Pyridine was distilled from potassium hydroxide pellets and 
o
stored over 4A molecular sieves.
Tetrahydrofuran was dried by stirring with powdered calcium
hydride overnight followed by distillation and stored under an
o
inert atmosphere over 4A molecular sieves.
Diethyl ether, ethyl acetate, hexane and water were all 
distilled.
Chloroform was used as supplied (May & Baker Ltd)
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HPLC Solvents
Acetonitrile and water were used as supplied (Rathburn Chem Co 
Ltd). The pH of solvent mixtures was adjusted by the addition of 
ammonia to the required pH.
Preparative tic
RP preparative tic was performed on Whatman PLKC 18F plates, 1 mm 
thickness. The product bands were identified under UV light and 
separated from the plate. The product was removed from the 
support by washing three times with methanol.
Reagents
Reagents were of the highest commercially available purity from 
the following suppliers: Aldrich Chem Co, BDH and Lancaster 
Synthesis.
n-Butyllithium was titrated against diphenylacetic acid in dry 
THF at room temperature immediately prior to use.
Instrumentation
R.P.HPLC was performed on a Perkin-Elmer series 3B liquid 
chromatograph. Analytical columns were Waters pBondapak C^g>
3.9 mm x 300 mm and used at a flow rate of 1 ml.min * unless
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otherwise stated. Preparative columns were Du Pont Zorbax 
21.2 mm x 250 mm and were used at a flow rate of 15 ml.min  ^
unless otherwise stated.
Normal phase pHPLC was performed on a Waters preparative 
LC/System 500-A using a single silica column 50 mm x 300 mm.
Mass spectra were obtained on a VG Analytical ZAB-HF mass 
spectrometer fitted with an Ion-Tech saddle field gun. Xenon was 
used as a reactant gas to provide an ion source and a 
thioglycerol matrix was used to assist ion formation. In 
practice, thioglycerol was smeared on the probe and then the 
sample applied in methanol solution. Approximately 20 pg of a 
leukotriene was required for a good spectrum. The trace was 
recorded by a UV oscilloscope as the signal half-life was too 
short for computer analysis, and calibrated by the cluster ions 
obtained from a glycerol FAB mass spectrum.
Melting points were determined on a Buchi 510 melting point 
apparatus and are uncorrected.
60 MHz nmr spectra were recorded on a Hitachi Perkin-Elmer 
high resolution nmr spectrometer R-24B.
1 13
90 MHz H nmr and C nmr spectra were recorded on a Bruker WH90 
pulse Fourier transform spectrometer.
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Optical rotations were determined on a Perkin-Elmer polarimeter 
241.
Short-distance distillation was performed on a Buchi GKR-50 
Kugelrohr apparatus
Ultra-violet spectra were recorded on a Perkin-Elmer Lambda 5 
UV/VIS spectrophotometer.
Analytical Methods
CHN analysis was performed by CHN Analysis Ltd.
FAB-mass spectra were recorded by M-Scan Ltd.
De-Salting Method
Waters sep-pak C^g cartridges were used for the de-salting of 
leukotrienes and analogues after deprotection by the following 
method. After removal of organic solvents under reduced pressure 
the solution containing the leukotriene salt was acidified to pH 
1 with 1 M HC1 and loaded via a syringe onto a Sep-pak which had 
been pre-wetted by elution with methanol (2 ml) followed by water 
(5 ml). The cartridge was then flushed with water (5 ml) and the 
leukotriene eluted as the free acid with methanol (5 ml).
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Preparation of Methyl 7-oxo-5(S),6(R)-oxidoheptanoate
(a) Methyl 5(S) , 6 (R),7-trihydroxyhept-2(E)-enoate (II)
2-Deoxy-D-ribose (135 g, 1 mol) and methoxycarbonylmethylene- 
triphenylphosphorane (340 g, 1.02 mol) were refluxed together in 
dry tetrahydrofuran (1 1) for 9 h. The solvent was removed at 
reduced pressure and the resultant syrup was dissolved in 
chloroform (1 1). The chloroform solution was thoroughly 
extracted with water; the aqueous extract was washed with 
chloroform then concentrated at reduced pressure. The resultant 
syrup was re-dissolved in chloroform (400 ml) and dried with 
magnesium sulphate. The solution was filtered and concentrated 
to give a white gum (199 g, 100 %).
Recrystallisation from dichloromethane/ether gave the title 
compound as white flakes (84 g, 42 %) m.p. 60-62°C, [c ]^p = -19.1° 
(C = 1.0, MeOH). A second crop of crystals may be obtained from 
the residue.
CHN Analysis: Found: C, 50.24; H, 7.46% Calculated for CgH^Oj.:
C, 50.52; H, 7.42 %
*H nmr (60 MHz, CDClg): 6 = 2.5 m, 2H, 4-CH2 ; 3.5 m, 2H, 7-CH2OH;
3.54 s, 3H, CO^H^; 4.1 m, 3H, 3 x OH (exchanges f>20 ) ; 5.85 d,
1H, 2-CH, J = 16Hz; 7.0 dd, 1H, 3-CH, J = 16Hz, J„ , = 8Hz.
Z ) j  Z ) j  j  > ^
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(b) Methyl 5 (S),6(R),7-trihydroxyheptanoate (III)
The heptenoate (II) (50 g, 0.26 mol) was dissolved in dry ethyl 
acetate (300 ml) together with 10% palladium on charcoal (5 g) 
and hydrogenated at atmospheric pressure until the theoretical 
quantity of hydrogen had been absorbed. The suspension was 
filtered through a pad of Celite and concentrated at reduced 
pressure to give a colourless oil. Crystallisation from 
dichloromethane-ether gave the title compound as white flakes, 
m.p. 45-47°C, [tfJD = “ 15° (C = 1.0, MeOH) (27 g, 53 %).
*H nmr (60 MHz, CDClg); 6 = 1.6 m, 4H, 3-CH2> 4-CH2 ; 2.4 m, 2H,
2-CH2 ; 3.62 s, 3H, C O ^ H g j  3.7 m, 4H, 5-CH(0H), 6-CH(0H),
7-CH(0H); 4.0 br, 3H, 3 x OH (exchanges D20 ) .
(c) Methyl 5(S),6(R)-dihydroxy-7-(p-toluenesulphonyloxy)- 
heptanoate (IV)
The heptanoate (III) (29 g, 0.151 mol) and p-toluenesulphonyl 
chloride (30 g, 0.157 mol) were dissolved in dry pryidine (380 
ml) and the resultant solution stirred for 25 h at -10°C. The 
solution was then poured into a mixture of ice, hydrochloric acid 
and dichloromethane (200 m l ) . During the mixing the temperature 
was kept below 20°C. The layers were separated and the aqueous 
phase was extracted three times with dichloromethane.
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The combined extracts were washed with brine, dried and 
concentrated at reduced pressure to give a sticky solid (52 g ) . 
Recrystallisation from ether gave the title compound as white 
needles (24.8 g, 47 %) m.p. 59-61°C, [tf]D = +3.03° (C = 1.09, 
CHClg).
CHN Analysis: Found: C, 52.29; H, 6.28; S, 8.92 % C ^ H ^ O ^ S  
requires: C, 52.00; H, 6.40; S, 9.26 %
XH nmr (60 MHz, CDClg): 6 = 1.6 m, 4H, 3-CH2 , 4-CH2 ; 2.3 m, 2H,
2-CH2 ; 2.39 s, 3H, CO^H^; 3.16 s, 2H, 2 x OH (exchange B^O) ;
3.60 s, 3H, C02CH3 ; 3.6 m, 2H, 5-CH(0H), 6-CH(0H); 4.12 d, 2H, 
7-CH2OTs, Jg 7 = 4Hz; 7.26 d, 2H, 2'-H, 6 '-H, J2 , 3 » = 8Hz; 7.76 
d, 2H, 3 f-H, 5 ’-H.
(d) Methyl 5 (S)-hydroxy-6 (S),7-oxidoheptanoate (V)
The tosylate (IV) (31.8 g, 92 mmol) was dissolved in dry methanol 
(127 ml) and anhydrous potassium carbonate (25.4 g, 0.184 mol) 
was added. The mixture was stirred for 45 min, then filtered and 
concentrated at reduced pressure. The residue was partitioned 
between aqueous ammonium chloride solution and chloroform (150 
m l ) . The aqueous phase was extracted twice more with chloroform. 
The combined extracts were washed with brine, dried and 
concentrated to give the title compound as a colourless oil (15.5 
8 * 97 %), [<*]D = +17.4° (C = 1.5, CHC13).
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XH nmr (60 MHz, CDC13) : 6 = 1.7 m, 4H, 3-CH2> 4-CH2 ; 2.3 t, 2H,
2-CH~, J0 = 7 Hz; 2.72 d, 1H, 7-CH.H , J. _ = 4 Hz; 2.8 m, 1H,Z Z)j A o
6-CH; 2.90 dd, 1H, 7-CH.H , J, . = 8 Hz, J. = 4 Hz; 3.60 s, 3H,A“D O) / Ay D
C02CH3 ; 3.6 m, 2H, CH(OH) (1H exchanges D20 ) .
(e) Methyl 7-hydroxy-5(S),6 (S)-oxidoheptanoate (VI)
The 6,7-epoxide (V) (15.5 g, 90 mmol) was dissolved in dry 
methanol (60 ml) and anhydrous potassium carbonate (12.4 g, 90 
mmol) was added. The mixture was stirred at room temperature for 
28 h then filtered, concentrated at reduced pressure and 
partitioned between aqueous ammonium chloride solution and 
chloroform (100 ml). The aqueous phase was extracted twice more 
with chloroform. The combined extracts were washed with brine, 
dried and concentrated to give the title compound as a colourless 
oil (6.4 g, 82 %), [oG d = -30.2° (C = 1.7, CHC13) .
*H nmr (60 MHz, CDC13) : 6 = 1.6 m, 4H, 3-CH2> 4-CH2 ; 2.4 m, 2H,
2-CH2 ; 2.8 m, 2H, 5-CH, 6-CH; 3.6 m, 3H, 7-CH20H (1H exchanges
D20); 3.62 s, 3H, C02CH3 .
(f) Methyl 7-oxo-5(S),6 (R)-oxidoheptanoate (I)
The alcohol (VI) (1.65 g, 9 mmol) was dissolved in dry
dichloromethane (20 ml) and added to a solution of dipyridinium
chromate in dry dichloromethane (330 m l ) . After 10 min the
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mixture was poured onto the top of a column of silica (ca. 200 
cm3) and eluted under pressure with dichloromethane (1.5 1) to 
give the title compound as a yellow oil (1.22 g, 74 %), [0^]^ = 
+ 68° (C = 1.3, CHC13).
This was purified by chromatography on silica with hexane/ethyl 
acetate (4:1) plus triethylamine (0.5 %) to give a pale yellow 
oil (1.17 g, 71 %), [tf]D = +94.2° (C = 1.2, CHC13) .
*H nmr (60 MHz, CDC13) : <5 = 1.7 m, 4H, 3-CH2 , 4-CH2 ; 2.4 m, 2H,
2-CH_; 3.15 dd, 1H, 6-CH, J c , = 2.0 Hz, J, _ = 6.0 Hz; 3.2 dt,
Z 3,0 O , /
1H, 5-CH, J4 5 = 6.0 Hz; 3.62 s, 3H, C02CH3 ; 9.01 d, 1H, CHO.
Methyl 5(S),6(S)-oxido-ll-oxo-7(E),9(E) undecadienoate (VII)
(a) The aldehyde (I) (1.2 g, 7 mmol) was dissolved in dry 
dichloromethane (30 ml) and slowly added to a solution of 
4-oxobut-2(E)-enyltriphenylphosphorane (VIII) (2.8 g, 8.5 mmol) 
in dry dichloromethane (30 ml) over 1.5 h. The solution was 
stirred for a further 2 h at room temperature then concentrated 
at reduced pressure to give a sticky, dark red solid. This was 
chromatographed on silica gel with ether/hexane (plus 0.5 % 
triethylamine) to give as colourless oils the pure 7(Z) isomer 
(268 mg), [c/]p = -49.0° (C = 1.8, CHC13) and mixtures with the 
(E) isomer (692 m g ) .
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*H nmr (60 MHz, CDC13> : 6 = 1.7 m, 4H, 3-CH2> 4-CH2 ; 2.4 m, 2H,
2-CH2 ; 3.0 m, 1H, 5-CH; 3.6 m, 1H, 6-CH; 3.63 s, 3H, C02CH3 ; 5.55 
dd, 1H, 7-CH, J, = 8 Hz, J. = 11 Hz; 6.15 dd, 1H, 10-CH,O , / / , o
Jg 1Q = 15 Hz, J 1Q u  = 8 Hz; 6.35 dd, 1H, 8-CH, J ? g = 11 Hz,
Jg 9 = 12 Hz; 7.66 dd, 1H, 9-CH; 9.62 d, 1H, CHO.
b) The combined fractions (960 mg, 4.3 mmol) were dissolved in 
dry dichloromethane (40 ml) with a trace of iodine (6 mg) and the 
solution stirred (in sunlight) for 3 h. This was concentrated 
at reduced pressure to give a yellow solid which was rapidly 
chromatographed on silica with ether (plus 0.25 % triethylamine) 
to give a yellow solid (919 m g ) . Recrystallisation from 
ether-hexane gave the title compound as yellow needles 
(716 mg, 75 %), m.p.59-60°C, [o(]D = -37.0° (C = 1.0, CHC13) .
CHN Analysis: Found: C, 63.96; H, 7.06; 0, 28.88 % ^^2^16^4 
requires: C, 64.27; H, 7.19; 0, 28.54 %.
XH nmr (90 MHz, CDC13) : 6=  1.73 m, 4H, 3-CH2> 4-CH2 ; 2.40 t, 2H,
2-CH-, J0 ~ = 6.59 Hz; 2.92 dt, 1H, 5-CH, J, _ = 5.56 Hz, J c . =
Z Z j J T) J J ) u
2.05 Hz; 3.22 dd, 1H, 6-CH, Jg ? = 7.32 Hz; 3.68 s, 3H, C02CH3 ;
5.96 dd, 1H, 7-CH, J7 Q = 14.93 Hz; 6.16 dd, 1H, 10-CH, J Q in =
/ > o y i j.u
15.08 Hz, J 1Q n  = 7.61 Hz; 6.63 dd, 1H, 8-CH, Jg g = 10.83 Hz; 
7.10 dd, 1H, 9-CH; 9.58 d, 1H, CHO.
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Preparation of 4-oxo-2(E)-butenylidenetriphenylphosphorane (XI)
a) l-Bromo-4-oxobut-2(E)-ene (IX)
1-Acetoxy-1,3-butadiene (29.5 g, 0.26 mol) was dissolved in 
hexane (120 ml) with barium carbonate (60 mg) and cooled to 
-78°C. To this stirred solution was added bromine (43.7 g, 0.28 
mol) in carbon tetrachloride (150 ml) dropwise over 75 min. The 
solution was then allowed to warm to room temperature. Sodium 
bicarbonate (50 g) and water (220 ml) were added and the mixture 
shaken mechanically for 3 h in a conical flask fitted with a 
steam distillation splash head. The phases were separated and 
the aqueous layer extracted with chloroform. The combined 
extracts were washed with brine, dried and concentrated to yield 
a pale yellow oil (50.3 g ) . This product was immediately vacuum 
distilled to afford a clear oil (29.4 g, 76 %) , b.p. 49-52°C/0.8 
mBar.
1H nmr (60MHz, CDC13) : 6 = 4.05 d, 2H, CH2B r , ^  2 = 7 Hz; 6,20 
dd, 1H, 3-CH, J2 3 = 16 Hz, ^  4 = 7Hz; 6.90 dt, 1H, 2-CH; 9.55 
d, 1H, CHO.
b) 4-0xobut-2(E)-enyltriphenylphosphonium bromide (X)
l-Bromo-4-oxobut-2(E)-ene (IX) (29.4 g, 0.20 mol) was dissolved 
in acetone (120 ml) and cooled to 0°C. Triphenylphosphine
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(57.6 g, 0.22 mol) was added to this mechanically stirred 
solution which was allowed to return to room temperature 
overnight. The precipitate thus formed was filtered off under an 
inert atmosphere, washed with acetone (2 x 100 ml) and vacuum
dried to afford a cream solid (82.0 g, 100 %) m.p. 180.5-182°C.
c) 4-0xo-2(E)-butenylidenetriphenylphosphorane (XI)
4-0xobut-2(E)-enyltriphenylphosphonium bromide (X) (82.0 g, 0.20 
mol) was added to dichloromethane (600 ml) and sodium hydroxide
solution (300 ml; 1 M) in a separating funnel. The mixture was
shaken for 5 min and then separated. The aqueous phase was 
further extracted with dichloromethane (400 m l ) . The combined 
extracts were washed with brine, dried and filtered. Diethyl 
ether (3 1) was added to this solution and cooled to -20°C 
overnight. The title compound was collected as dark red 
crystalline solid (38.6 g, 58 %; m.p. 160-165°C), washed with 
diethyl ether, dried and stored under argon in amber bottles at 
0°C.
Preparation of 3(Z)-nonenyltriphenyphosphonium tosylate (XIV)
(a) 3(Z)-Nonen-1-ol (XII)
3-Nonyn-l-ol (10.5 g, 75 mmol) dissolved in dry, distilled 
methanol (100 ml) containing 5 % Pd/BaSO^ catalyst (400 mg) 
poisoned with quinoline (400 jjI) was stirred vigorously under an
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atmosphere of hydrogen until the theroetical quantity of hydrogen 
(1.6 1) had been absorbed and hydrogen uptake had ceased. The 
reaction misture was filtered through Celite and concentrated to 
yield 3(Z)-nonen-l-ol (10.7 g, quantitative yield) as a yellow 
oil.
*H nmr (60MHz, CDC13) : 6 =  0.90 t, 3H, 9-CH3 , Jg g = 6 Hz; 1.3 m, 
6H, 6-CH2 , 7-CH2 , 8-CH2 ; 2.3 m, 5H, 2-CH2 , 5-CH2> OH (1H 
exchanges D20 ) ; 3.6 t, 2H, CH20H, 2 = 6.5 Hz; 5.45 m, 2H,
3-CH, 4-CH.
(b) 3(Z)-Nonenyl-p-toluenesulphonate (XIII)
3-Nonen-l-ol (XI) (10.6 g, 75 mmol) dissolved in dry, distilled 
pyridine (50 ml) was cooled to 0°C under argon. Recrystallized 
p-toluenesulphonyl chloride (17.1 g, 90 mmol, 1.2 equivalents) 
was added and the reaction stirred overnight (approximately 
16 h) at 0°C before quenching on crushed ice (100 g ) . The 
product was extracted twice with ether (200 m l ) , washed with 
brine (200 ml), dried and concentrated. The crude product was 
eluted through a short silica pad with dichloromethane to give a 
pale yellow oil (19.4 g, 88 % yield).
*H nmr (60MHz, CDC13) : 6 =  0.87, t, 3H, 9'-CH3 , Jgl g1 = 6 Hz;
1.25 m, 6H, 6 f-CH2 , 7 ’-CH2 , 8 f-CH2 ; 1.90 m, 2H, 2'-CH2 ; 2.3 m,
5H, 5 f-CH2 , 4-CH3 ; 3.98 t, 2H, l'-CH^ 2 , = 6.8 Hz; 5.32 m, 
2H, 3'-CH, 4'-CH; 7.53 dd.
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(c) 3 (Z)-Nonenyltriphenylphosphonium tosylate (XIV)
(XII) (19.3 g, 65 mmol) and recrystallized triphenylphosphine 
(17.0 g, 65 mmol, 1 equivalent) were heated under gentle reflux 
at 90°C in acetonitrile (25 ml) for 48 h. The solvent was 
removed under reduced pressure and the product recrystallized 
from dichloromethane/diethyl ether (100 ml/150 ml) to give 
3(Z)-nonenyltriphenylphosphonium tosylate (24.0 g, 66 % yield) as 
white needles m.p. 77-80°C.
CHN Analysis: Found: C, 71.45; H, 6.92; N, 0.00; Cl, 1.96; S,
5.52; P, 5.33 % Calculated for C ^ H ^ O ^ S :  C, 71.56; H, 6.92; N,
0.00; Cl, 2.16; S, 5.59; P, 5.40 %
Methyl 5(S),6(S)-oxido-7(E),9(E),11(Z),14(Z)-eicosatetraenoate
(LTA.-Me) (VIII)
 4----
The phosphonium tosylate (XIII) (3.59 g, 6.43 mmol) was dissolved 
in dry tetrahydrofuran (100 ml) and cooled to -20°C under argon. 
n-Butyllithium solution (5.89 mmol) in hexane was added dropwise 
and stirred for 5 min at -20°C before cooling to -78°C. After a 
further 10 min hexamethylphosphoramide (12.2 ml; 12 equivalents) 
in tetrahydrofuran (12.2 ml) was slowly added and stirred for 15 
min before addition of the aldehyde (VII) (1.2 g, 5.36 mmol) in 
tetrahydrofuran (5 ml). The reaction mixture was stirred at 
-78°C for 30 min and then quenched with methanol (1 ml),
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allowing the reaction temperature to slowly rise to room 
temperature (1 h ) .
The product was partitioned between diethyl ether and water, 
washed well with further water and brine, dried over magnesium 
sulphate and concentrated. The crude product was purified by 
rapid column chromatography on silica (previously deactivated by 
standing for 3 h in the eluent), eluting with hexane/diethyl 
ether/triethylamine (88 : 10 : 2; 250 ml) under argon pressure. 
The eluent, upon concentration, yielding the desired LTA^,-Me 
(1.80 g, 100 % yield).
A m a X (cyclohexane): 271, 280.8 ( £ =  50,000), 292.6 nm.
*H nmr (90 MHz, CDC13) : (5 = 0.89 t, 3H, 20-CH3 , 3 ^  2Q = 6 Hz; 
1.29 s, 6H, 17-,18-,19-CH2 ; 1.7 m, 4H, 3-,4-CH2 ; 2.06 m, 2H, 
16-CH2 ; 2.38 t, 2H, 2-CH2 J£ 3 = 6.7 Hz; 2.93 m, 3H, 13-CH2 , 5-H; 
3.13 dd, 1H, 6-H, J, , = 2 Hz, J, = 7.9 Hz; 3.67 s, 3H, C0oCHQ ;
J j D O ) / J
5.4 m, 4H, 7-,12-,14-,15-H; 6.3 m, 4H, 8-,9-,10-,11-H.
13C nmr (23 MHz, CDC13) : 6 = 14.1, 20-CH3 ; 21.3-33.6, 8X CH2 ; 
51.6, C02CH3 ; 58.3, 5-CH; 60.5, 6-CH; 126.9-134.6, 8X CH=; 173.6, 
co2ch3 .
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6(R)-S-(Glutathione)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)-
eicosatetraenoic acid (LTC^)
Leukotriene methyl ester (100 mg, 0.3 mmol) was dissolved in
methanol/triethylamine (1:1; 1.5 ml) containing dimethyl 
N-trifluoroacetylglutathionate (195 mg, 0.45 mmol) and stirred at 
room temperature under an atmosphere of argon for 6 h, by which 
time acidification of a UV sample indicated complete consumption 
of LTA^-Me. The crude product was purified by reverse phase 
preparative tic (RP ptlc) (CH^CN/^O 4:1; Rf 0.5-0.7) to yield 
protected LTC^ (210 mg, 91% yield; UV (MeOH) A y = 280.9 nm,
£ =  50,000). The product was re-purified by reverse phase 
preparative HPLC (RP-HPLC) (CH3CN/H20 70:30; flow 15 ml.min” 1, Tr 
= 15 min) and subsequently deprotected by the action of lithium 
hydroxide (100 mg) in tetrahydrofuran/water (1:1; 10 ml) over 2 
h. The product was de-salted on a reverse phase plug to yield 
the title compound in high purity (167 mg, 89 % yield; UV (H20)
A = 281.8 n m , 6 = 40,000). HPLC Analysis: CHoCN/Ho0/Ac0H
nicix *5 2.
40:60:0.1 pH 5.6, flow 1.0 ml.min 1, Tr = 7.0 min, 93 % 11-cis
isomer, 5 % 11-Trans isomer. FAB MS (+ve ion): M  +  H, 625 au.
6(R)-S-(Cysteinylglycine)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)- 
eicosatetraenoic acid (LTD^)
Leukotriene A^ methyl ester (100 mg, 0.3 mmol) was dissolved in 
methanol/triethylamine (1:1, 2 ml) containing methyl 
N-trifluoroacetylcysteinylglycinate (210 mg, 0.6 mmol) and
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stirred at room temperature under argon for 5 h. By this time,
acidification of a UV sample indicated the reaction to be
complete so the reaction mixture was quenched by applying it to
reverse phase ptlc plates and eluting with acetonitrile/water
(4:1). The crude product (Rf 0.42-0.69; 170 mg, 90 % yield; UV
(MeOH) A = 280.9 nm, 6 =  50,000) was purified by RP HPLC max J
(CH^CN/^O 70:30; flow 15 ml.min Tr = 19 min) to give
protected LTD^ in high purity (99 % by HPLC) (120 mg, 64 %
yield). Deprotection was effected in a solution of lithium
hydroxide (100 mg) in tetrahydrofuran/water (1:1; 10 ml) over 6 h
and de-salted on a reverse phase plug to give the title compound
in good yield (95 mg, 64 % yield; UV (Ho0) A = 281.9 nm, £=
2 max
40,000). HPLC analysis: CH3CN/H20/Ac0H 50:50:0.1 pH.5.6 , flow 
1.0 ml.min \  Tr = 5.3 min. 95 % 11-cis isomer, 5 % 11-Trans 
isomer. FAB MS (-ve ion): M  - H, 495 au.
6(R)-S-(Cysteine)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)- 
eicosatetraenoic acid (LTE^)
LTA^-Me (50 mg, 0.15 mmol) was dissolved in methanol/ 
triethylamine (1:1, 1 ml) containing methyl
N-trifluoroacetylcysteinate (66 mg, 0.3 mmol) and stirred at room
temperature under an atmosphere of argon for 2 h. Preparative
tic (RP CH3CN/H20 5:1) afforded the crude protected product (Rf
0.35-0.5) (38 mg, 45 % yield; UV (MeOH) A = 280.8 nm,
max
6 = 50,000) which was further purified by RP HPLC (CH3CN/H20 
75:25; flow 15 ml.min Tr = 20 min) to give pure protected LTE^
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(25 mg, 29 % yield). Deprotection was effected with lithium 
hydroxide (50 mg) in tetrahydrofuran/water (1:1, 5 ml) over 3 h 
and subsequent de-salting furnished the title compound (19 mg,
29 % yield; UV (1^0) = 280.6 nm, £= 40,000). HPLC Analysis:
CH3CN/H20/H3P04 45:55:0.1 pH 3.7, flow 1.0 ml.min” 1, Tr = 12 min, 
95 % 11-cis isomer, 3 % 11-Trans isomer.
Preparation of sodium 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-
2-hydroxypropoxyj-4-oxo-8-propyl-4H-l-benzopyran-2-carboxylate 
(FPL 55712) (XXII)
(a) 4-0-Allylresacetophenone (XVI)
Resacetophenone (100 g, 0.658 mol) was dissolved in acetone 
(300 ml) containing allyl bromide (88 g, 1.1 eq) and potassium 
carbonate (120 g, 1.3 eq) and refluxed with stirring for 6 h.
When cool, the reaction mixture was concentrated and partitioned 
between 1 M  hydrochloric acid and ether, the organic layer 
separated and the aqueous phase re-extracted with further ether.
The combined ether extracts were shaken with 4 M  sodium hydroxide 
solution and the resultant sodium salt collected by filtration 
and washed with ether. The salt was re-converted to the phenol 
by treatment with 5 M hydrochloric acid and extracted twice with 
ether. The combined extracts were washed with water, dried 
(MgSO^) and concentrated. The crude product was distilled 
(116-120°C/2.0 mbar) to give a pale yellow oil (108 g, 85 % 
yield).
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nmr (60 MHz, Acetone): 6 = 2.50 s, 3H, CH^; 4.60 d, 2H, CH2> 
J = 5 Hz; 5.35 m, 2H, CH=CH2 ; 6.00 m, 1H, CH=CH2 ; 6.45 m, 2H,
3-H, 5-H; 7.75 d, 1H, 6-H, 6 = 9 Hz; 12.65 s, 1H, OH.
(b) 3-Allylresacetophenone (XVII)
4-O-Allylresacetophenone (197 g, 1.03 mol) was heated at 
210-215°C, with stirring under argon, for 1.5 h. A red solid was 
obtained upon cooling which was purified by sublimation 
140-150°C/1 mbar) to give a pale yellow crystalline solid (180g,
91 % yield, mp 133°C (lit97 132-3°C).
*H nmr (60 MHz, d^ Acetone): 6 = 2.50 s, 3H, CH^; 3.40 d, 2H, CH2>
J = 6 Hz; 4.95 m, 2H, CH=CH2 ; 5.95 m, 1H, CH=CH2 ; 6.45 d, 1H,
5-H, J c = 9 Hz; 7.55 d, 1H, 6-H; 9.00 br, 1H, 4-0H; 13.00 s,
5,6
1H, 2-0H.
(c) 3-Propylresacetophenone (XVIII)
3-Allylresacetophenone (28 g, 0.146 mol) was dissolved in ethanol 
(250 ml) containing 10 % Pd/C catalyst (2.8 g) and vigorously 
stirred under a slight pressure of hydrogen. The reaction was 
stopped when the theoretical absorption of hydrogen had taken 
place and the rate of absorption had dropped considerably. The 
solution was filtered through Celite and concentrated to afford a 
white solid which recrystallised from chloroform to yield white 
plates (23 g, 81% yield), m.p. 128.5-9.5°C, (lit97 127-8°C).
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^H nmr (60 MHz, Acetone) 5 = 0.90 t, 3H, CH^-CH^, J = 7 Hz;
1.55 m, 2H, CH2-CH3 ; 2.50 s, 3H, C(0)CH3 ; 2.60 t, 2H, Ar-CH2 , J = 
7 Hz; 6.40 d, 1H, 5-H, J5 g = 9 Hz; 7.50 d, 1H, 6-H; 8.90 br, 1H,
4-0H; 13.15 s, 1H, 2-0H.
(d) 4 1-(2,3-Epoxy)propoxy-3f-propylresacetophenone (XIX)
3-Propylresacetophenone (50 g, 0.258 mol) and epichlorohydrin
(71.6 g, 3 eq) were brought to reflux, with stirring, in ethanol
(75 ml). Dropwise, at reflux, was added a solution of potassium
hydroxide (15.9 g, 1.1 eq) in ethanol (75 ml) and water (1.5 ml).
After a further 2 h of reflux, the reaction mixture was
concentrated and partitioned between ether and water. The ether
layer was separated, dried (MgSO^) and concentrated to give a
yellow oil which solidified on standing. The product was
distilled (148-150°C/0.2 mbar) to give a pale yellow solid on
cooling, which recrystallised from 40-60° petrol yielding
94
off-white crystals (42 g, 65 % yield), mp 57-8°C, (lit 54-5°C).
^H nmr (60 MHz, d^ Acetone) 6 = 0.90 t, 3H, CH2~CH3 , J = 7 Hz;
1.55 m, 2H, CH2-CH3 ; 2.55 s, 3H, C(0)CH3 ; 2.75 m, 4H, Ar-CH2 , 
Ar-0-CH2 ; 3.35 m, 1H, 0-CH; 4.20 m, 2H, 0-CH2 ; 6.60 d, 1H, 5-H,
Jc , = 9 Hz; 7.70 d, 1H, 6-H; 12.85 s, 1H, OH.
J ) o
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(e) Ethyl 7-hydroxy-8-propyl-4-oxo-4H-l-benzopyran-2-carboxylate
(XX)
3-Propylresacetophenone (90 g, 0.464 mol) and diethyloxalate (95 
ml, 2.2 eq) were dissolved in a mixture of ethanol (110 ml) and 
ether (110 ml). This was added to a stirred solution of sodium 
ethoxide (1.86 mol; 4 eq) prepared from sodium (42.7 g) and 
ethanol (600 ml) and the mixture refluxed under argon for 3 h. 
When cool, the reaction mixture was poured into an excess of 
2 M  hydrochloric acid (1200 ml) and extracted with ether. The 
ether extracts were washed with water, dried (MgSO^,) and 
concentrated under reduced pressure to afford the intermediate 
of.y-diketo ester (XXIII) as an oil.
The oil was refluxed in ethanol (350 ml) containing c. HC1 (6 ml)
for 45 min, concentrated to near-dryness and partitioned between
ethyl acetate and water. The organic layer was washed with
saturated sodium hydrogen carbonate solution, water; dried
(MgSO^) and concentrated to give a yellow solid.
Recrystallisation from ethyl acetate/hexane (2:1) afforded the
title compound as yellow powdery crystals (80 g, 62% yield), mp 
94
168-8.5°C (lit 166-7°C).
XH nmr (60 MHz, d. Acetone): 5 = 1.00 t, 3H, CH0-CH--CH-, J = 7 
o 2 2. — 5
Hz; 1.40 t, 3H, C(0)CH2-CH3 , J = 7 Hz; 1.60 m, 2H, CH2-CH2-CH3 ;
2.90 t, 2H, CH2-CH2-CH3 ; 4.40 q, 2H, C(0)-CH2-CH3 ; 6.80 s, 1H,
3-H; 7.00 d, 1H, 5-H, J c , = 9Hz; 7.80 d, 1H, 6-H; 9.50 br, 1H,
5,0
OH.
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(f) Ethyl 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-
hydroxypropoxy3-4-oxo-8-propyl-4H-l-benzopyran-2-carboxylate
(XXI)
4 ’-(2,3-Epoxy)propoxy-3’-propylresacetophenone (15 g, 0.060 mol) 
and ethyl 7-hydroxy-8-propyl-4-oxo-4H-l-benzopyran-2-carboxylate 
(15 g, 0.054 mol) were dissolved in dimethylformamide (75 ml) 
containing N-benzyltrimethylammonium hydroxide (60j j1 ; 40 % in 
methanol) and refluxed under argon for 2 h. The resulting brown 
solution was concentrated to a viscous oil (30 g ) .
The crude product was dissolved in dichloromethane and purified 
by normal phase preparative HPLC (silica) using diethyl ether as 
eluent, to give the ester as an off-white solid (9.3 g, 29 % 
yield) m.p. 135-141°C (Lit97 121-3°C).
lE nmr (60 MHz, CDC13) ; 5 =  0.90 m, 6H, 2X CH2-CH2-CH3 ; 1.50 m,
7H, 2X CH2-CH2-CH3 , C(0)-CH2-CH3 ; 2.50 s, 3H, C(0)CH3 ; 2.70 m,
4H, 2X CH2-CH2-CH3 ; 4.35 m, 8H, C(0)-CH2-CH3 , 0-CH2-CH(0H)-CH2-0;
6.40 d, 1H, 6 fH, J , = 9 Hz; 6.95 m, 2H, 3-H, 5-H,; 7.55 d,
5 , 0
1H, 5'-H; 7.95 d, 1H, 6-H, J5 6 = 9 Hz; 12.65 s, 1H, 3 f-0H.
(g) Sodium 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2- 
hydroxypropoxy]-4-oxo-8-propyl-4H-l-benzopyran-2- 
carboxylate (FPL 55712) (XXII)
The ester (XXI) (9.3 g) was saponified by refluxing for 1 h with
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sodium hydrogencarbonate (9.3 g) in 10 % aqueous ethanol (125 ml) 
and the free acid isolated by dichloromethane extraction of the 
acidified solution. The acid was neutralised with sodium 
hydrogencarbonate, twice recrystallised from water and 
freeze-dried to give the title compound as white crystalline 
flakes (7.5 g, 82 % yield).
CHN Analysis: Found: C, 60.80; H, 5.77 %. C ^ H ^ O ^ N a .  0.71 H 20
requires C, 60.81; H, 5.75 %.
5(S)-Hydroxy-6(R)-methylthio-7(E),9(E),11(Z),14(Z)- 
eicosatetraenoic acid (A-l)
LTA^-Me (50 mg, 0.15 mmol) was dissolved in methanol/
triethylamine (1:1; 5 ml) and methane thiol bubbled slowly
through the mixture for 8 h. The reaction was shown by HPLC
(CH3CN/H20 90:10 flow 1.0 ml.min” 1 Tr (LTA^-Me) = 7 . 9  min, Tr
(product) = 7.2 min) to be approximately 80 % complete at this
stage so the reaction vessel was sealed and left to stir for a
further 16 h to reach completion. The reaction mixture was
concentrated under reduced pressure and applied in acetonitrile
to two RP ptlc plates, eluting with acetonitrile/water (4:1).
The product (Rf 0.21-0.36) was extracted from the stationary
phase with methanol (16.8 mg; UV(MeOH) A = 279.8 nm, £ =
r max
50,000) and purified by RP HPLC (CH3CN/H20 75:25 flow 20 ml.min” 1 
Tr = 23.5 min) to yield the desired methyl 
5 (S)-hydroxy-6(R)-methylthio-7(E),9(E),11(Z),14(Z)-
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eicosatetraenoate (11.5 mg by UV determination). The product was 
deprotected by the action of lithium hydroxide (50 mg) in aqueous 
tetrahydrofuran (THF/H^O 1:1; 5 ml) over 30 min, (the extent of 
reaction was followed by RP HPLC CH^CN/^O/AcOH 80:20:0.1 pH 5.6; 
Tr (product) = 7.5 min) concentrated under reduced pressure to 
remove the tetrahydrofuran and acidified in HC1 to pH 1.0. 
De-salting on a reverse-phase plug yielded the title compound. (9 
mg, 16 % yield; UV(H20) A max = 281.3 nm, 6 = 40,000). FAB MS(-ve 
ion): M  - H, 365 au. FAB MS (+ve ion): M +  Na, 389 au; M  - H +  
2Na, 411 au.
N-Trifluoroacetylcysteamine
Cysteamine hydrochloride (11.35 g, 0.1 mol) was stirred in 
trifluoroacetic acid (50 ml) under argon at room temperature 
until complete dissolution was obtained (approximately 10 min). 
The solution was then cooled to 0°C and trifluoroacetic anhydride 
(18 ml; 1.3 eq) slowly added. The reaction mixture was stirred
at 0°C for 30 min then at room temperature for 1 h before being
concentrated to dryness. The crude product 22 g; 4.7 g above 
theoretical) smelled strongly of trifluoroacetic acid so was 
dissolved in methylene chloride and swirled with alumina. After 
filtration and concentration this yielded the title compound in 
38 % yield (6.5 g).
XH nmr (60 MHz, CDC13) : 5 = 1.5 t, 1H, SH, J = 7 Hz; 2.8 m, 4H,
cii2"c-2 ; 7,8 br* 1H* NH’
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5 (S)-Hydroxy-6(R)-2,-aminoethylthio-7(E),9(E),11(Z),14(Z)-
eicosatetraenoic acid (A-2)
LTA^-Me (50 mg, 0.15 mmol) was dissolved in methanol/
triethylamine (1:1; 5 ml) containing N-trifluoroacetylcysteamine
(260 mg, 1.5 mmol, 10 eq) and stirred at room temperature under
argon for 1 h. The solution was then concentrated to near
dryness, applied to two RP ptlc plates and eluted with
acetonitrile/water (5:1). The product (Rf 0.47) was extracted
with methanol (13.1 mg; UV(MeOH) A = 280.5nm, 6 = 50,000) and
max
purified by preparative RP HPLC (CH^CN/^O/AcOH 75:25:0.1 pH 5.6, 
flow 15 ml.min Tr = 26 min). The protected product was 
saponified by the action of lithium hydroxide (50 mg) in 
tetrahydrofuran/water (1:1, 5 ml), followed by analytical HPLC in 
the afore-mentioned solvent system (flow 1 ml.min 1 Tr (product) = 
8 min; Tr (protected) = llmin (broard)). Deprotection was 
complete after 2 h and the solution neutralised with 1 M  HC1, 
de-salted on a reverse-phase plug to yield the title compound.
(4.2 mg, 7 % yield; UV(H20) A max = 280.1 nm, 6 = 40,000).
FAB MS (-ve ion): M  - H, 394 au; M  +  Cl, 430 au. FAB MS (+ve 
ion): M +  H, 396 au.
5 (S)-Hydroxy-6(R)- 2 f-carboxyethylthio-7(E),9(E),11(Z),14(Z)- 
eicosatetraenoic acid (A-3)
LTA^-Me (25 mg, 0.075 mmol) was dissolved in methanol/
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triethylamine (1:1; 2.5 ml) containing methyl
3-mercaptopropionoate (83 pi, 0.75 mmol) and stirred under argon
for 17 h. The reaction mixture was concentrated, dissolved in
acetonitrile and applied to a RP ptlc plate, eluting with
acetonitrile/water (4:1). The product (Rf 0.27-0.37) was
extracted with methanol to yield the desired methyl
5 (S)-hydroxy-6 (R)- 2 f-(methoxycarbonyl)ethylthio-7(E),9(E),11(Z),
14(Z)-eicosatetraenoate (12 mg; UV(MeOH) A = 280.3 nm
max
6 = 50,000). This product was considered pure enough to continue 
without preparative HPLC purification and was saponified by the 
action of lithium hydroxide (50 mg) in aqueous tetrahydrofuran 
(THF/H^O 1:1, 5 ml) over 30 min (the reaction being followed by 
RP HPLC CH3CN/H20/Ac0H 80:20:0.1 pH 5.6 flow 1.0 ml.min”1 Tr 
(protected) = 11 min; Tr (product) = 5 min). The saponification 
mixture was concentrated, acidified to pH 1.0 with 1 M  HC1 and 
de-salted on a reverse-phase plug to yield the title compound.
(9.6 mg, 30 % yield; UV(H20) A max = 280.1 nm, 6 = 40,000).
1H nmr (protected) (90 MHz, CDCl^): 6 =  0.89 t, 3H, 20-CH^, 2q
= 5.5 Hz;. 1.28 m, 6H, 17-,18-,19-CH2 ; 1.7 m, 4H, 3-,4-CH2 ; 2.00 
s, 1H, OH; 2.03 m, 2H, 16-CH2 ; 2.34 t, 2-CH2 , J£ 3 = 7 Hz; 2.58 
t, 3H, 2 f-CH2 , 6-H, J 1,.2 i = 5 -5 H z 5 2 -68 t> 2H> 13-CH2 , J 12 13>
J 13 14 = 5,2 Hz; 2,94 t * 2H* S_CH2 ; 3,42 d d * 1H, 5-H » J4 5 = 4,1 
Hz, J c , = 9.1 Hz; 3.66 s, 3H, l-C0oCHo ; 3.69 s, 3H, 2'-C0oCHo ; ^f O Z j Z j
5.6 m, 4H, 7-,12-,14-,15-H; 6.28 m, 4H, 8-,9-,10-,11-H.
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5 (S)-Hydroxy-6(R)-2f-hydroxyethylthio-7(E),9(E),11(Z),14(Z)—
eicosatetraenoic acid (A-4)
LTA^-Me (50 mg, 0.15 mmol) was dissolved in methanol/
triethylamine (1:1; 5 ml) containing 2-mercaptoethanol (107 pi,
1.5 mmol) and stirred under argon at room temperature for 2.5 h.
The reaction mixture was concentrated under reduced pressure,
dissolved in acetonitrile and applied to two preparative RP tic
plates and eluted with acetonitrile/water (4:1). The product was
extracted with acetonitrile to give the methyl ester of the title
compound. (24.8 mg, 40 % yield; UV(MeOH) A = 279.9 nm, 6 =
max
50,000). Saponification was effected with lithium hydroxide (100
mg) in aqueous tetrahydrofuran ( T HF/^O 1:1, 10 ml) over 30 min,
following the reaction progress by RP HPLC (CH^CN/^O/AcOH
70:30:0.1 pH 5.6 flow 1.0 ml.min 1 Tr (ester) = 12.5 min, Tr
(product) = 7.0 min). The tetrahydrofuran was removed under
reduced pressure and the aqueous solution acidified with 1 M  HC1,
de-salted on a reverse phase plug to yield the title
compound.(22.8 mg, 38 % yield; UV(H90) A = 280.4 nm,
z max
8 = 40,000). 
l-Mercaptobutan-3-one
Methylvinylketone (7 g, 0.1 mol) was added slowly to a solution 
of sodium sulphide (48 g, 0.62 mol) in water (50 ml), maintaining 
the temperature below 15°C. After complete addition, the 
reaction mixture was stirred for 3 h at ambient temperature
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then poured onto crushed ice, neutralised to pH 7.0 with 
c.HCl and extracted with ether. The combined ether extracts were 
dried over magnesium sulphate, filtered and concentrated to yield 
the crude product (6.3 g ) . Short-distance distillation (70°C/5 
mbar) furnished the title compound as a colourless mobile oil. 
(2.6 g, 25 % yield).
lE nmr (60 MHz, CDC13) ; 5 = 1.65 t, 1H, SH, J = 8 Hz; 2.15 s, 3H, 
CH3 ; 2.70 m, 4H, CH2-CH2 .
5(S)-Hydroxy-6(R)-3,-oxobutanylthio-7(E),9(E),11(Z),14(Z)- 
eicosatetraenoic acid (A-5)
LTA^,-Me (25 mg, 0.075 mmol) was dissolved in methanol/
triethylamine (1:1; 2.5 ml) containing l-mercaptobutan-3-one (100
mg, 0.96 mmol, ca 13 eq) and stirred at room temperature under
argon for 6 h. HPLC (CH3CN/H20 90:10) indicated the reaction to
be approximately 75 % complete by this time so the solution was
concentrated, dissolved in acetonitrile and applied to two RP
ptlc plates, eluting with acetonitrile/water (5:1). The product
(Rf 0.3 - 0.44) was extracted with methanol (17 mg; UV(MeOH) A
° max
= 279.9 nm, 6 = 50,000) and purified by preparative RP HPLC 
(CH3CN/H20 70:30 flow 20 ml.min Tr = 22 min) to yield the 
title compound as its methyl ester (8.2 mg by UV determination). 
The ester was hydrolysed by the action of lithium hydroxide (50 
mg) in aqueous tetrahydrofuran (THF/H20 1:1, 5 ml) over 30 min, 
concentrated and acidified with 1 M  HC1. De-salting on a
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reverse-phase plug yielded the title compound in 19 % overall
yield (6 mg; UV(H 0) A = 281.0 nm, 6 = 40,000) 
z mHx
Methyl 5 (S),6(S)-oxido-7(Z)-nonadecenoate (XXIV)
n-Dodecyltriphenylphosphonium bromide (0.95 g, 1.86 mmol) was 
dissolved in dry, distilled tetrahydrofuran (15 ml) and cooled, 
with stirring under argon, to -78°C. A  solution of 
n-butyllithium in hexane (1.03 ml, 1.49 M; 1.53 mmol) was added 
dropwise, stirring for 10 min before the addition of HMPA (3.2 
ml, 18.4 mmol) in tetrahydrofuran (3.2 ml). After a further 10 
min methyl 5(S),6(R)-oxido-7-oxoheptanoate (53 mg, 0.31 mmol) 
dissolved in tetrahydrofuran (3 ml) was added, continuing 
stirring at -78°C for 15 min then at 0°C for 15 min before 
quenching with methanol (65 pi). The product was extracted with 
ether, washing well with water and brine, dried over magnesium 
sulphate and concentrated to dryness. Purification was effected 
by eluting rapidly through a short silica column with 2 % 
triethylamine/hexane to give the title compound as a pale yellow 
oil in quantitative yield (98.5 mg)
*H nmr (90 MHz, C D C 1 J : 6 =  0.88 t, 3H, 19-CH, J. Q 1Q = 6 Hz;
1 U } 1 y
1.26 s, 20H, 3-CH2 , 10-,19-CH2 ; 1.75 m, 2H, 4-CH2 ; 2.20 q, 2H, 
9-CH2 , Jg^9 = 6.8 Hz, J9>10 = 6.8 Hz; 2.39 t, 2H, 2-CH2 , J£ 3 =
6.5 Hz; 2.82 dt, 1H, 5-CH, 5 = 6.5 Hz, J5 6 = 1.5 Hz; 3.30 dd,
1H, 6-CH, J6 ? = 9 Hz; 3.68 s, 3H, C02Me; 5.08 t, 1H, 7-CH, J y g 
= 11 Hz; 5.71 dt, 1H, 8-CH.
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6(R)-S-(Cysteinylglycine)-5(S)-hydroxy-7(Z)-nonadecenoic acid and
5(S)-S-(cysteinylglycine) 6 (R)-hydroxy-7(Z)-nonadecenoic acid 
(A-6, A-7)
Methyl 5(S),6(S)-oxido-7(Z)-nonadecenoate (45.4 mg, 0.14 mmol) 
was dissolved with stirring under argon in methanol/triethylamine 
1:1 (5 ml) containing methyl N-trifluoroacetylcysteinylglycinate 
(250 mg, 6 eq). The temperature was raised to 40°C and the 
extent of reaction followed by RP HPLC (MeOH/^O 90:10 flow 2.0 
ml.min  ^ detect 200 nm; Tr (epoxide) = 7.6 min, Tr (major 
product) = 4.0 min; Tr (minor product) = 3.6 min). After 7 h the 
reaction was approximately 85 % complete so was left overnight 
(21 h in total) to reach completion. The crude reaction product 
was purified as before by RP ptlc, eluting with C H ^ C N / ^ O  9:1 (Rf 
0.5-0.75) and subsequently purified by RP preparative HPLC to 
separate the isomers (MeOH/^O 90:10 flow 15 ml.min detect 200 
nm, Tr (major) = 10.5 min, Tr (minor) = 7.6 min). The major 
isomer (25 mg) was identified by 1H nmr (90 MHz) as that 
resulting from 6-addition, dimethyl 5 (S)-hydroxy-6 (R)-S-(N- 
trifluoroacetylcysteinylglycinate)- 7 (Z)-nonadecenoate; and the 
minor isomer, identified similarly as that resulting from
5-addition, dimethyl 6 (R)-hydroxy-5(S)-S- 
(N-trifluoroacetylcysteinylglycinate)-7(Z)-nonadecenoate.
The protected products were saponified by the action of lithium 
hydroxide in aqueous tetrahydrofuran as before (3 h reaction
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time) and de-salted to give the title compound (23 mg and 3 mg 
respectively 38 % combined yield).
A-6 (Protected)
lE nmr (90 MHz, CDClg):5 = 0.88 t, 3H, 19-CHg, J lg ig = 6 Hz; 1.26
s, 18H, [10-19]-CH2 ; 1.63 quintet, 2H, 3-CH2> J2 g = 7.5 Hz, Jg 4
= 7.5 Hz; 1.82 m, 3H, 4-CH2> 5-CH(OH); 2.05 m, 2H, 9-CH2 ; 2.37 t,
2H, 2-CH ; 2.62 m, 1H, 6-CH; 2.74 dd, 1H, S-CH.(H_), J A _ = 14 
Z ""A 15 A) 1j
Hz, J lf ol = 7.9 Hz; 3.08 dd, 1H, 5-CH.(HtJ), J. , = 5.5 Hz;
1 y Z A  — 15 I , Z
3.67 s, 3H, 1-C02CH3 ; 3.79 s, 3H, C02CH3 (glycinyl); 3.84 dt, 1H,
5-CH, J4 5 = 4.5 Hz, J5 6 = 4.5 Hz; 4.09 d, 2H, HN-CH2-C02CH3 , J 
= 5.3 Hz; 4.60 q, 1H, HN-CH-CH2 , J = 7 Hz; 5.43 dt, 1H, 7-CH,
J, = 2 Hz, J7 0 = 11 Hz; 5.73 dt, 1H, 8-CH, J G _ = 4.4 Hz; 7.07
o ) / / >o o j y
t, 1H, NH-CH2 , J = 4.7 Hz; 7.59 d, 1H, NH-CH, J = 5.7 Hz.
A-7 (Protected)
1Hmnr (90 MHz, CDC13) : 6= 0 .88 t, 3H, 19-CH3 , J lg 19 = 6 Hz; 1.26 
s, 20H, [10,19]-CH2 , 3-CH2 ; 1.85 m, 2H, 4-CH2 ; 2.05 m, 2H, 9-CH2 ; 
2.36 t, 2H, 2-CH2 ; 2.57 m, 1H, 6-CH; 3.01 s, 3H, 5-CH2 , 5-CH(OH); 
3.49 s, 3H, C02CH3 (glycinyl); 3.67 s, 3H, 1-C02CH3 ; 3.90 m, 1H,
6-CH; 4.08 m, 2H, HN-CH2-C02CH3 ; 4.44 m, 1H, NH-CH-CH2 ; 5.32 t,
1H, 7-CH, 0 = 11 Hz; 5.71 dt, 1H, 8-CH; 6.78 br, 1H, NH; 7.03
/»O
br, 1H, NH.
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Methyl 5(S),6(S)-oxido-7(E),9(E),11(Z)-heptadecatrienoate (XXV)
n-Hexyltriphenylphosphonium bromide (0.88 g, 2.0 mmol) was 
dissolved in dry, distilled tetrahydrofuran (15 ml) and cooled to 
-78°C under argon. Freshly titrated n-butyllithium solution in 
hexane (1.15 ml, 1.49 M  soln; 1.7 mmol) was slowly added and the 
mixture stirred for 10 min at -78°C before the addition of HMPA 
(3.5 ml, 12 eq) in tetrahydrofuran (3.5 ml). After a further 10 
min at -78°C, methyl 5(S),6(S)-oxido-ll-oxoundec-7(E),9(E)- 
dienoate (76.7 mg, 0.34 mmol) in tetrahydrofuran (3 ml) was 
slowly added, stirred for 15 min at -78°C then raised to 0°C for 
a further 15 min before quenching with methanol (0.5 ml). The 
product was extracted with ether, washing with water and brine, 
dried and concentrated. Purification was effected by rapid 
elution through a short silica column with hexane/2 % 
triethylamine to give, upon concentration, the title compound in 
37 % yield (37 mg)
A max 270.2, 279.5, 291.5 nm (cyclohexane); HPLC Analysis (SiO^) 
Hexane/EtOAc/TEA 98.5 : 0.5 : 1.0 flow 2.0 ml.min  ^ Tr = 5.5 min 
(cis), Tr = 8.2 min (trans) 92 % cis; 8 % trans; no other 
appreciable impurities.
6(R)-S-(Cysteinylglycine)-5(S)-hydroxy-7(E),9(E),11(Z)- 
heptadecatrienoic acid (A-8)
Methyl 5(S),6(S)-oxido-7(E),9(E),11(Z)-heptadecatrienoate (25 mg;
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0.086 mmol) was dissolved in methanol/triethylamine 1:1 (2.5 ml) 
containing methyl N-trifluoroacetylcysteinylglycinate (100 mg; 
0.34 mmol, 4 eq) and stirred under argon at room temperature for 
6 h. After this time RP HPLC (CH^CN/^O 90:10 flow 1.0 ml.min *) 
indicated the reaction to have virtually stopped (75 % conversion 
Tr (epoxide) = 7.5 min; Tr (product) = 4.9 min). The product was 
purified by RP ptlc (CH^CN/H^O 4:1; Rf 0.65-0.80) to yield the 
desired product (13.7 mg by UV determination; 28 % yield).
Saponification was conducted in tetrahydrofuran-water (1:1;
10 ml) containing lithium hydroxide (100 mg) over 4 h 
(following the extent of reaction by RP HPLC CH^CN/^O/AcOH 
60:40:0.1 pH 5.6); which after de-salting, yielded the title 
compound (4.75 mg; 12 % yield) A max - 280.9 nm.
Methyl 5(S),6(S)-oxido-7(E),9(E),11(Z)-tridecatrienoate (XXVI)
Ethyltriphenylphosphonium bromide (370 mg, 1 mmol) was suspended 
in dry, distilled tetrahydrofuran (10 ml) at room temperature 
under argon and a solution of n-butyllithium in hexane (640 pi, 
1.40 M; 0.9 mmol) added dropwise. After 15 min the reaction was 
cooled to -78°C and HMPA (1.9 ml; 11 mmol) in tetrahydrofuran 
(1.9 ml) added, stirring for 10 min before the addition of methyl 
5(S),6(S)-oxido-ll-oxoundec-7(E),9(E)-dienoate (100 mg;
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0.45 mmol) in tetrahydrofuran (0.5 ml). After a further 15 min 
the reaction was quenched with methanol (250 pi), brought to room 
temperature and extracted with ether, washed well with water and 
brine, dried (MgSO^) and concentrated. The crude product was 
purified by eluting rapidly through a silica column (25 x 100 mm) 
with hexane/ether/triethylamine (88:10:2; 400 ml) under argon 
pressure and concentrated to give the title compound in 69 % 
yield (73 m g ) .
5 (S)-Hydroxy-6 (R)-S-(cysteinylglycine)- 7 (E),9(E),11(Z)- 
tridecatrienoic acid (A-9)
Methyl 5 (S),6(S)-oxido-7(E),9(E),11(Z)-tridecatrienoate (73 mg,
0.31 mmol) was dissolved in methanol/triethylamine (1:1; 1 ml) 
containing methyl N-trifluororacetylcysteinylglycinate (200 mg;
0.69 mmol, 2.2 eq) and stirred under argon at room temperature 
for 3 h. After this time RP HPLC (CH3CN/H20 90:10; flow 1.0 
ml.min ^) showed the reaction to be complete (Tr (epoxide) = 3 . 9  
min; Tr (product) = 3 . 1  min) and the product was semi-purified by 
preparative RP ptlc (CH3CN/H20 4:1; Rf 0.7-1.0) to give the title 
compound in protected form (118 mg by UV determination; 73 % 
yield). A small sample was purified by preparative RP HPLC 
(CH3CN/H20 40:60; 20 ml.min *) to give a pure sample for ^H nmr and 
deprotection.
Saponification of the product (6.5 mg) was conducted in 
tetrahydrofuran/water (1:1; 5 ml) containing lithium hydroxide
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(50 mg) over 4 h (following the extent of reaction by RP HPLC
CH^CN/^O/AcOH 30:70:0.1 pH 5.6); which, after de-salting,
yielded the title compound in 87 % yield (4.3 mg; UV(H_0) Az nicLx
277.8 nm, 6 = 40,000) FAB MS (-ve ion): M  - 2H +  Na, 422 au.
A-9 (Protected)
lE nmr (90 MHz, CDC13) : 5 = 1.61 m, 4H, [3,4]-CH2 ; 1.78 d, 3H, 
13-CH3 , J12 13 = 6.1 Hz; 2.36 t, 2H, CH2-CH2-C02CH3 , J£ 3 = 7 Hz; 
2.5 m, 1H, 6-H; 2.78 dd, 1H, S-CH.H , J. = 14 Hz, J A = 7.5
~~A ii A , B A , X
Hz; 3.04 dd, 1H, S-CHAH , v = 6 Hz; 3.57 dt, 1H, 5-H, J, _ =
A— iJ ii, A  H , D
9 Hz, J5 6 = 4 Hz; 3.67 s, 3H, 1-C02CH3 ; 3.77 s, 3H, C02CH3 
(glycinyl); 4.08 d, 2H, NH-Ch2-C02CH3> J = 5.3 Hz; 4.64 q, 1H, 
CH2-CH-NH, J = 6.8 Hz; 5.6 m, 2H, 7-H, 12-H; 6.3 m, 4H, [8-11]-H; 
7.04 t, 1H, CH -NH, J = 4.5 Hz; 7.55 d, 1H, CH-NH, J = 6.8 Hz.
6 (R)-Carboxymethylthio-5(S)-hydroxy-7 (Z),9(Z),11(E),14(E)- 
eicosatetraenoic acid (A-10)
LTA^-Me (25 mg, 0.075 mmol) was dissolved in methanol/ 
triethylamine (1:1; 0.5 ml) containing ethyl 2-mercaptoacetate 
(90 mg, 0.75 mmol, 10 eq) and stirred under argon at room 
temperature for 3 h. After this time acidification of a sample 
did not significantly effect the recorded UV spectrum so the 
reaction was deemed complete. The reaction mixture was purified 
by RP ptlc (Rf 0.18 - 0.50) eluting with CH3CN/H20 4:1 to yield 
the desired protected material (31.6 mg by UV; 93 % yield). The
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product was shown to contain some material resulting from
trans-esterification of the ethyl ester in methanol but with this
exception was of high purity and was subsequently deprotected 
without further purification. The product was deprotected by the 
action of lithium hydroxide (100 mg) in aqueous tetrahydrofuran 
(1:1; 10 ml) over 15 min and de-salted on a RP.plug to yield the
title compound in 69 % overall yield (21.2 mg). RP HPLC
CH3CN/H20/Ac0H 55:45:0.1 pH 5.6 Tr = 8.3 min.
6(R)-(3f-Carboxypropylthio)-5(S)~hydroxy-7(E),9(E),11(Z),14(Z) 
eicosatetraenoic acid (A-ll)
LTA^-Me (25 mg, 0.075 mmol) was dissolved in methanol/ 
triethylamine (1:1; 1 ml) containing methyl 4-mercaptopropanoate 
(50 mg, 0.37 mmol) and stirred under argon at ambient temperature 
for 24 h. The reaction mixture was purified by RP ptlc to 
afford the protected analogue (26.9 mg; UV(MeOH) A max = 280.4 nm, 
6 = 50,000). Deprotection was performed using lithium hydroxide 
(100 mg) in aqueous tetrahydrofuran (1:1; 10 ml) at room 
temperature over 1.5 h. The product was de-salted on a reverse 
phase plug to yield the title compound (23.2 mg; UV(MeOH) A =
HlcL2£
280.9 nm, £ = 50,000) shown by RP HPLC (CH3CN/H20/Ac0H 60:40; 0.1
pH 5.6) to only be 73 % pure (Tr = 12 min). The product was
re-purified by preparative HPLC to furnish the title compound
(7.9 mg; UV(Ho0) A = 281.5 nm, 6 = 40,000).i. max
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6(R)-(4t-Carboxybutylthio)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)
eicosatetraenoic acid (A-12)
LTA^-Me (25 mg, 0.075 mmol) was dissolved in methanol/
triethylamine (1:1; 1 ml) containing methyl 4-mercaptobutyrate
(41 mg, 0.28 mmol) and stirred under an inert atmosphere for 24
h at room temperature. The crude reaction mixture was purified
by RP ptlc to yield the protected analogue (19.1 mg; UV(MeOH)
A = 280.6 nm, £= 50,000). Purification was effected by RP * max J
pHPLC (CH^CN/H^O 90:10, Tr = 6.9 min) to yield the title compound
as the dimethyl ester (5.5 mg by UV determination). The product
was deprotected by the action of lithium hydroxide (50 mg) in
aqueous tetrahydrofuran 1:1; 5 ml) over 5 h to yield the title
compound after de-salting (11.8 mg; UV(H00) A = 281.2 nm,z in 3.x
e =  40,000) RP HPLC (CH3CN/H20/Ac0H 60:40:0.1 pH 5.5) indicated
the product to only be 75 % pure Tr = 13.0 min) being
contaminated with 12 % of the 11-trans isomer (Tr = 14.6 min) and
so was re-purified on RP pHPLC to give the pure title compound
(5.2 mg; UV(Ho0) A = 281.6 nm, £ =  40,000).
2 max
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6(R)-(6t-Carboxyhexylthio)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)-
eicosatetraenoic acid (A-13)
LTA^-Me (25 mg, 0.075 mmol) was dissolved in methanol/
triethylamine (1:1; 1 ml) containing methyl 7-mercaptoheptanoate
(100 mg; 0.56 mmol) and stirred under argon for 6 days at room
temperature. The reaction mixture was then concentrated and
purified by RP ptlc, eluting with CH^CN/H^O (5:1) to afford the
protected analogue (24 mg by UV determination; 67 % yield). The
product was purified by RP pHPLC (CH^CN/H^O 80:20; tr = 20 min)
to give the title compound as its dimethyl ester 5.3 mg by UV
determination; A m a x (MeOH) 280.9 nm). Deprotection was effected
by the action of lithium hydroxide (50 mg) in 50 % aqueous
tetrahydrofuran (5 ml) over 1.5 h and the product de-salted in
the usual manner to afford the title compound (4.9 mg, 0 7 ( ^ 0 )
A 281.5 nm. HPLC RP CHoCN/Ho0/Ac0H 80:20:0.1 pH 5.6 
max 3 2
tr = 7.4 min).
6(R)-[(±)-l'-Carboxyethylthio]- 5 (S)-hydroxy-7(E),9(E),11(Z),14 (Z) 
-eicosatetraenoic acid (A-14, A-15)
(±)-Thiolactic acid (67 pi, 0.753 mmol, 10 eq) was treated with 
excess diazomethane in ether, concentrated under reduced pressure 
and dissolved in methanol/triethylamine 1:1 (0.5 ml). This 
solution was added to LTA^-Me (25 mg; 0.0753 mmol) and stirred
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for 2 h at room temperature after which time acidification of a 
UV sample indicated complete reaction. Purification by RP ptlc 
(CH3CN/H20 4:1; Rf 0.18 - 0.44) yielded a mixture of 
diastereomers (27.6 mg; 81 % combined yield) which were seperable 
by HPLC (RP CH3CN/H20 70:30; flow 1.0 ml.min" 1 Tr = 24.5 min Tr =
26.8 min). The purified diasteromers were separately deprotected 
by the action of lithium hydroxide in aqueous tetrahydrofuran as 
before, and de-salted to yield analogues A-14 and A-15. HPLC 
CH3CN/H20/Ac0H 60:40:0.1 pH 5.6; A-14 Tr = 6.9 min; A-15 Tr = 8.2 
min. FAB MS (-ve ion): M  - H, 423 au for both analogues.
Methyl 2-methyl-2-thiopropanoate
To a solution of 2-bromoisobutyric acid (3.34 g, 20 mmol) in 
water (50 ml) was added sodium hydrogensulphide hydrate (6 g,
106 mmol) and the mixture heated to 100°C for 2 h. The
reaction was cooled to ambient temperature, acidified to pH 2, 
saturated with sodium chloride and extracted with ether (3 x 50 
m l ) . The combined ether extracts were dried (MgSO^) and 
evaporated to a small volume. To this solution was added 
dropwise an ethereal solution of diazomethane until a yellow 
colour persisted. The solution was purged with argon and
evaporated in vacuo to give a pungent oil which was purified by
distillation (68-70°C/20 mbar) (0.8 g, 30 % yield).
*H nmr (60 MHz, CDC13) : <5 = 1.4 s, 6H, C(CH3)2 ; 1.6 s, 1H, 5H; 3.8 
s, 3H, C02CH3 .
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6(R)-[1 '-Carboxy-l'-methylethylthio]^(S)-hydroxy-7 (E),9(E),
11(Z),14(Z)-eicosatetraenoic acid (A-16)
LTA^-Me (14.8 mg, 0.045 mmol) and methyl 2-methyl-2-thio- 
propanoate (60 mg, 0.45 mmol; 10 eq) were stirred together at 
room temperature under argon in a solution of methanol (300 pi) 
and N,N-diethylcyclohexy.lamine (100 pi). After an 8 h reaction 
time the crude product was purified by RP preparative HPLC 
(CH^CN/^O 80:20 flow 6 ml.min \  Tr = 13.2 min) to give the 
title compound as its dimethyl ester (5.15 mg, 25 % yield). UV 
(MeOH) A max = 280 nm. The product was deprotected with lithium 
hydroxide (75 mg) in a solution of methanol (3 ml) and water 
(3 ml) over 6.5 h to yield the title compound after de-salting 
in the usual fashion (4.81 mg, 25 % yield). UV (MeOH) A max - 281 
nm.
Methyl 3-chloro-2(R)-methylpropanoate
Methyl 3-hydroxy-2(S)-methylpropanoate (12.5 g, 105.8 mmol) was 
dissolved in dry dichloromethane (20 ml) containing imidazole 
(300 mg) and stirred at 0°C under argon. Thionyl chloride 
(20 ml, 274 mmol) was added slowly over 10 min and the reaction 
mixture maintained at 0°C for a further 1.5 h before raising 
the temperature to reflux for 30 min. The title compound was 
isolated by distillation (52-54°C/38 mbar) in 84 % yield 
(12.1 g). [tf] (C = 1.0, CHC13) = +15.3°
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*H nmr (60 MHz, CDC13) : 5 =  1.3 d, 3H, CH-CH3 , J = 7 Hz; 3.0 tq, 
1H, J2 3 = 2 Hz; 3.7 d, 2H, 3-CH2 ; 3.8 s, 3H, C02CH3 .
Methyl 2 (R)-methyl-3-thiopropanoate
Methyl 3-chloro-2(R)-methylpropanoate was converted by the 
previously described method into the title compound (bp 70-75°C/
26 mbar).
1 c
H nmr (60 MHz, CDC13) : 0 =  1.3 br.d, 3H, CH-CH3 ; 3.0 m, 4H, 2-CH, 
3-CH2 ,SH; 3.7 s, 3H, C02CH3 .
6 (R)-[2 *(R)-Carboxypropylthio]-5(S)-hydroxy-7(E),9(E),11(Z), 
14(Z)-eicosatetraenoic acid (A-17)
LTA^-Me (22.5 mg, 0.068 mmol) and methyl 2(R)-methyl-3-
thiopropanoate (50 mg, 0.37 mmol; 5 eq) were stirred in a
solution of methanol (500 pi) and N,N-diethylcyclohexylamine
(200 pi) at ambient temperature for 3 h. The product was
purified by RP preparative HPLC (CH3CN/H20 70:30, flow 3.0
ml.min \  Tr = 79 % yield). A sample of the protected material
(11.25 mg, 24 pmol) was saponified in a solution of methanol (2
ml) and water (2 ml) containing lithium hydroxide (50 mg) to give
the title compound after de-salting (9.0 mg, 68 % overall yield).
UV(MeOH) A = 280 nm. 
max
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Methyl 2(S)-methyl-3-thiopropanoate
Methyl 3-chloro-2(S)-methylpropanoate [tf]D (C = 1.07, CHCl^) = 
-14.9° (lHnmr as for methyl 3-chloro-2(R)-methylpropanoate) was 
prepared from 3-hydroxy-2(R)-methylpropanoic acid as before and 
subsequently converted into the title compound as previously 
described (lHnmr as for the R - isomer).
6(R)-[2f(S)-Carboxypropylthio3- 5 (S)-hydroxy-7(E),9(E),11(Z), 
14(Z)-eicosatetraenoic acid (A-18)
LTA^-Me (20 mg, 0.060 mmol) and methyl 2(S)-methyl-3-thio- 
propanoate (30 mg, 0.22 mmol; 3.7 eq) were dissolved in a 
solution of methanol (250pl) containing
N,N-diethylcyclohexylamine (125 pi), and stirred under argon at
ambient temperature for 3 h. Purification by RP preparative
HPLC (CH3CN/H20 70:30, flow 3.0 ml.rain"1, Tr = 36 min) yielded
the title compound as the dimethyl ester (7.93 mg, 28 % yield).
The product was deprotected by the action of lithium hydroxide
(50 mg) in aqueous methanol (1:1; 4 ml) over 2 h and de-salted
to give the title compound (6.15 mg, 23 % overall yield).
UV(MeOH) A = 280 nm. 
max
Methyl 3-mercapto-2,2-dimethylpropanoate
3-Chloropivalic acid (2.7 g, 20 mmol) was dissolved in water
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(40 ml) containing sodium hydrogensulphide (6.0 g, 106 mmol) and
refluxed for 16 h. The reaction mixture was then cooled,
acidified with c. H„S0., saturated with sodium chloride and
2 4
extracted with ether (3 x 50 m l ) . The combined ether extracts 
were dried over magnesium sulphate and concentrated.
Esterification with diazomethane in ether yielded the title 
compound (2.4 g, 80 % yield) which was purified by distillation 
(1.5 g, 50 % purified yield).
1 c
H nmr (60 MHz, CDC13) : 0 = 1.3 s, 6H, C(CH3)2 ; 1.6 t, 1H, SH, J 
= 4 Hz; 2.4 d, 2H, CH2 ; 3.8 s, 3H, C02CH3 .
6(R)-[2>-Carboxy-2l-methylpropylthio]-5(S)-hydroxy-7(E),9(E),
11(Z),14(Z)-eicosatetraenoic acid (A-19)
LTA^-Me (15 mg, 0.045 mmol) and methyl 3-mercapto-2,2-dimethy1-
propanoate (30 mg, 0.20 mmol; 4.4 eq) were dissolved in methanol
(400 jjI) containing N,N-diethylcyclohexylamine (100 jjI) and the
reaction mixture stirred under argon at ambient temperature for 5
h. The crude product was purified by RP preparative HPLC
(CH3CN/H20 70:30, flow 4.5 ml.min *, Tr = 25 min) to give the
title compound as the dimethyl ester (6.5 mg, 32 % yield).
Saponification was effected by the action of lithium hydroxide
(50 mg) in aqueous methanol (1:1, 4 ml) over 2 h. De-salting
in the usual manner furnished the title compound. (6.10 mg, 30 %
overall yield). UV(MeOH) A = 280 nm.J max
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Methyl-2-mercaptobenzoate
2-mercaptobenzoic acid (10 g) was dissolved in methanol (200 ml) 
and refluxed for 4 h with c. sulphuric acid (20 ml). The 
solution was partially concentrated of reduced pressure and 
poured into water. The mixture was extracted with ether (2 x 120 
ml) and the combined organic extracts were washed with sodium 
hydrogencarbonate solution, brine, dried (MgSO^) and concentrated 
to give cream crystals.
6(R)-(2t-Carboxyphenylthio)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)- 
eicosatetraenoic acid (A-20)
LTA^,-Me (25 mg, 0.075 mmol) was dissolved in tetrahydrofuran/ 
triethylamine (1:1; 1 ml) containing methyl thiosalicylate (126 
mg; 0.75 mmol). Potassium tertiary butoxide (84 mg; 0.75 mmol) 
was added slowly (over 10 min) and the reaction mixture stirred 
at room temperature for 16 h. The crude product was purified 
by RP ptlc followed by RP pHPLC (CH3CN/H20 90:10 tr = 8 min) to 
yield the title compound as its dimethyl ester (6.2 mg; A ma 
(MeOH) = 280.8 nm). Deprotection was effected in 50 % aqueous 
tetrahydrofuran (5 ml) containing lithium hydroxide (50 mg) over 
3 h. De-salting in the usual manner afforded the title 
compound (4.8 mg). FAB MS (-ve mode): M  - H, 471 au.
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Methyl 3-mercaptobenzoate
3-Aminobenzoic acid (13.7 g, 0.1 mol), sodium nitrite (6.9 g, 0.1 
mol) and sodium hydroxide (4.4 g, 0.11 mol) were dissolved in 
water (80 ml) and slowly added to a solution of 4 M  hydrochloric 
acid (107 ml) at -5°C. The mixture was stirred for 1 h and then 
a solution of ethyl potassium xanthate (48 g, 0.3 mol) added, the 
temperature being raised to 70°C for 1 h before cooling and 
acidifying to precipitate the xanthate ester which was collected.
lE nmr (60 MHz, CDC13) : 5 = 3.85 s, 4H, SH, CH3 ; 7.20 t, 1H, 5-H,
J4 5* J5 6 = 8 H z » 7*40 d, 1H, 4H; 7.8 d, 1H, 6-H; 7.95 s, 1H, 
2-H.
Hydrolysis was effected by heating on a steam bath for 30 min 
with 4 M  sodium hydroxide solution (50 m l ) . The solution was 
cooled and acidified to precipitate the disulphide of the title 
compound. The product was collected by filtration and refluxed 
for 24 h with powdered zinc (25 g) in acetic acid (200 m l ) .
The reaction mixture was then filtered and acidified with c. 
hydrochloric acid (400 ml) . The resulting precipitate was washed 
with water, collected and dried by dessication over silica gel to 
yield the title compound as a beige powder, mp. 142-145°C 
(lit*^ 142-145°C). The acid was esterified in methanol 
containing c. sulphuric acid as before to yield the title 
compound.
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6(R)-(3f-Carboxyphenylthio)-5(S)-hydroxy-7 (E),9(E),11(Z), 14(Z)
-eicosatetraenoic acid (A-21)
LTA^-Me (25 mg, 0.075 mmol) was dissolved in tetrahydrofuran/ 
triethylamine (1:1; 1 ml) containing methyl 3-mercaptobenzoate 
(126 mg, 0.75 mmol). Potassium tertiary butoxide (84 mg, 0.75 
mmol) was added slowly and the reaction mixture stirred at room 
temperature for 3 h. The reaction mixture was purified by RP 
ptlc and pHPLC (CH3CN/H20 90:10 tr = 13.8 min) to yield the 
protected analogue (7.8 mg; UV (MeOH) ^ max = 282 nm). 
Deprotection was effected by the action of lithium hydroxide (50 
mg) in 50 % aqueous tetrahydrofuran (5 ml) over 4 h at room 
temperature to yield, after de-salting, the title compound (7.0 
mg; HPLC CH3CN/H20/Ac0H 90:10:0.1 pH 5.6 tr = 4.0 min). FAB MS 
(-ve mode): M  - H, 471 au.
Methyl 4-mercaptobenzoate
4-aminobenzoic acid was diazotised and reacted with ethyl
potassium xanthate in an analogous manner to that described for
methyl 3-mercaptobenzoate. Hydrolysis and cleavage of the
104
disulphide furnished the free acid (mp 219-221°C, Lit 
216-219°C) which was esterified as before to yield the title 
compound.
^H nmr (60 MHz, CDC13) : 5 = 3.65 s, 1H, SH; 3.85 s, 3H, CH3 ; 7.2 
d, 2H, 3,5-H J_ = 8 Hz; 7.85 d, 2H, 2,6-H.
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6(R)-(4t-Carboxyphenylthio)-5(S)-hydroxy-7(E),9(E),11(Z),
14(Z)-eicosatetraenoic acid (A-22)
LTA^-Me (0.3 mg, 0.90 mmol) was dissolved in tetrahydrofuran/
triethylamine (1:1; 3 ml) was stirred under argon at room
temperature with methyl 4-mercaptobenzoate (1.5 g, 11 mmol) for 3
h. The crude product was purified by RP ptlc followed by RP
pHPLC (CH^CN/I^O 80:20) to yield the title compound as its
dimethyl ester (tr = 20 min, 132 mg; 29 %). Treatment with
lithium hydroxide (126 mg) in tetrahydrofuran/water (1:1; 4 ml)
under argon at room temperature for 20 h afforded the title
compound (130 mg, 28 % yield; UV(MeOH) A = 278.5 nm. FAB MS
max
(-ve mode): M - H, 471 au.
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SPECTRA
^H nmr (60 MHz, CDCl^)
Methyl 5(S),6(R),7-trihydroxyheptanoate (III)
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Methyl 5 (S) , 6 (R)-dihydroxy-7-(p-toluenesulphonyloxy)-heptanoate (IV)
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1H nmr (60 MHz, CDC13)
Methyl 7-oxo-5(S),6(R)-oxidoheptanoate (I)
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*H nmr (60 MHz, CDC13)
Methyl 5(S),6(S)-oxido-ll-oxo-7(E),9(E)-undecadienoate (VII)
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H nmr (90 MHz, CDC13)
Methyl 5(S),6(S)-oxido-7(E),9(E),11(Z),14(Z)-eicosatetraenoate
(LTA^-Me) (XIII)
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13c nmr (23 MHz, CDC13)
Methyl 5 (S),6(S)-oxido-7(E),9(E),11(Z),14(Z)-eicosatetraenoate
(LTA^-Me) (XIII)
-176
*H nmr (90 MHz, CDC13)
Methyl 5 (S)-hydroxy-6(R)-(2 f-methoxycarboxyethylthio)-7(E),9(E)
11 (Z),14(Z)-eicosatetraenoate (A-3 - Prot)
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LH nmr (90 MHz, CDC13)
Methyl 5(S),6(S)-oxido-7(Z)-nonadecenoate (XXIV)
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Dimethyl 5 (S)-hydroxy-6(R)-S-(N-trifluoroacetylcysteinyl-glycinate) 
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XH nmr (90 MHz, CDC13)
Dimethyl 6 (R)-hydroxy-5(S)-S-(N-trifluoroacetylcysteinyl-glycinate)
- 7 (Z)-nonadecenoate (A-7 - Prot)
uo
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iH nmr (90 MHz, CDCl^)
Dimethyl 5 (S)-hydroxy-6 (R)-S-(N-trifluoroacetylcysteinylglycinate)-
7(E),9(E),11(Z)-tridecatrienoate (A-9 -Prot)
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UV (MeOH)
Determination of the extent of reaction between LTA.-Me
4
and methyl N-trifluoroacetylcysteinylglycinate
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UV (H20)
6 (R)-S-(Glutathione)- 5 (S)-hydroxy-7(E), 9(E)
11(Z),14(Z)-eicosatetraenoic acid (LTC^)
HM
-184-
UV (H20)
6 (R)-S-(Cysteinylglycine)- 5 (S)-hydroxy-7(E),
9(E),11(Z),14(Z)-eicosatetraenoic acid (LTD^)
a-;
85-
■C Abi'' MANUAL:0D
-135-
UV (H20)
5 (S)-Hydroxy-6(R)- 2 '-carboxyethylthio-?(E),9(E)
11(Z),14(Z)-eicosatetraenoic acid (A-3)
-186-
UV (Cyclohexane)
Methyl 5 (S),6(S)-oxido-7(E),9(E),11(Z)
heptadecatrienoate (XXV)
233 333 353
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UV (H20)
5(S),Hydroxy-6(R)-S-(Cysteinyl%lycine)-7(E),
9(E),11(Z)-tridecatrienoic acid (A-9)
■j=.
-188-
5 (S)-Hydroxy-6(R)-methylthio-7(E),9(E),11(Z),14(Z)—
eicosatetraenoic acid (A-1)
-189-
5 (S)-Hydroxy-6(R)-methylthio-7(E),9(E),11(Z),14(Z)~
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